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Abstract 
A License to Kill: Understanding Natural Killer Cell Licensing to Fight Cancer 
 
 
Jolie Rae Schafer, B.S. 
 
 (Advisor: Dean A. Lee, MD, PhD; Shulin Li, On-Site Advisor) 
 
 
           Natural killer (NK) cell education is an essential developmental process for NK cell 
effector function, that renders some NK cells “licensed” and others “unlicensed” (with heightened 
or lowered effector function potential, respectively) against tumor and targets lacking self-
molecules. However, the underlying mechanisms responsible for the heightened effector 
responses of licensed cells remain unknown. Using NK cells derived from humans and expanded 
ex vivo we performed high-throughput protein expression analysis, and identified multiple 
proteins that are differentially regulated in licensed and unlicensed human NK cells before and 
after inhibition by killer-cell immunoglobulin-like receptors (KIRs) and activation by the NKp46 
natural cytotoxicity receptor, including several related to cellular metabolic pathways. We 
explored cellular metabolism in the two subsets and found that licensed NK cells are highly 
glycolytic, and use glycolysis and mitochondrial respiration for cytolysis of leukemia targets, 
whereas unlicensed NK cells are dependent on mitochondrial respiration. We determined the 
metabolic pathways that are necessary for licensed and unlicensed NK cells to elicit a cytolytic 
response using metabolic inhibitors to inhibit glycolysis or mitochondrial respiration metabolic 
pathways in the NK cells during a cytotoxicity assay. We observed that licensed NK cells utilize 
both glycolysis and mitochondrial respiration to perform cytolysis whereas unlicensed NK cells 
only use mitochondrial respiration for their cytolytic response against leukemia targets. To our 
knowledge, this is the first description of the underlying mechanisms that explain the cytolytic 
differences between licensed and unlicensed NK cells. Our findings provide a groundbreaking 
platform to further explore and manipulate metabolism in licensed and unlicensed NK cells to 
improve NK cell immunotherapy. 
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Chapter 1: Introduction 
1.1 Natural Killer Cell Biology 
Natural killer (NK) cells represent one component of the innate arm of the immune system. 
NK cells are leukocytes that differentiate from common lymphoid progenitor cells. NK cells 
constitute between 10-15% of peripheral blood lymphocytes. NK cells are identified by the 
expression of CD56 and CD16, and lacking expression of CD3 and CD19, as well as other 
lineage markers. Peripheral blood NK cells are predominantly composed of the CD56dim 
CD16bright mature highly cytolytic NK cells, along with a smaller percentage of CD56bright 
CD16dim immature NK cells that are great cytokine producers. NK cells kill their target cells by 
secreting cytotoxic granules, perforin and granzyme B, or through engagement of TRAIL or 
FASL death receptor pathways. NK cells also secrete pro-inflammatory cytokines, IFN-g and 
TNF-a, and chemokines that aid in the recruitment of the adaptive immune system. NK cells are 
the first responders to viral infections and cancer or transformed cells.  
 
NK cells express germline encoded cell surface receptors and do not express rearranged 
antigen specific receptors like other lymphocytes such as B cells and T cells.  NK cells act to 
alert and recruit the adaptive immune system when danger is present. NK cells engage targets 
using an array of receptors on the cell surface that include both activating and inhibitory 
receptors. The engagement and strength of the signal from the various activating and inhibitory 
receptors determines whether a NK cell will become activated and elicit a response. Upon 
activation, a NK cell will release cytotoxic granules and or cytokines by degranulation in the 
direction of the target cell. The killer-cell immunoglobulin-like receptor (KIR) family is the 
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primary focus of my project. KIRs can be activating or inhibitory, however my project has 
focused on inhibitory KIR. Inhibitory KIRs provide two major functions for NK cells. First, 
they aid in discriminating self from non-self and induce tolerance to prevent NK cells from 
attacking self, thereby providing protection from autoimmunity. Second, inhibitory receptors 
provide an important education signal that “license” and educate NK cells to kill cells that are 
missing human leukocyte antigen (HLA) such as in the case of leukemia, other cancers and viral 
infections. NK cell education will be explained in further detail below. 
 
Receptors 
KIRs are found on human, primate and cattle NK cells. The murine counterpart of KIRs 
are Ly49 receptors. KIRs and Ly49 receptors recognize major histocompatibility complex class 
I ligands (MHC I), also referred to as human leukocyte antigen (HLA) in humans. KIR 
expression is acquired later in NK cell development and is found primarily on mature NK cells 
(Beziat et al., 2010). There is discrepancy in the field as whether KIR acquisition is stochastic or 
whether KIR acquisition is dependent upon MHC-I expression, as there is evidence for both of 
these hypotheses (Beziat et al., 2010; Sleiman et al., 2014). KIRs have heterogeneity at many 
levels; functional (inhibitory or activating), haplotype, expression, ligand, and allelic diversity, 
and all contribute to the complexity of KIRs. The KIR haplotypes are A and B (Uhrberg et al., 
1997). The A haplotype is characterized by the presence of all of the inhibitory KIR genes and 
no activating KIRs (Uhrberg et al., 1997). The B haplotype is defined by the presence of any 
combination of activating KIR genes (Uhrberg et al., 1997). For my project, I only used donors 
with KIR A haplotype to eliminate any influence activating KIRs may have on NK cell 
function. KIRs have expression diversity, NK cells express multiple combinations of different 
KIRs and varying levels of KIR expression (Cheent and Khakoo, 2009). Each KIR has a 
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different HLA binding group ligand; KIR ligands will be discussed below. Lastly, there is allelic 
diversity; different KIR alleles have varying protection against diseases, variable expression and 
binding affinities to their ligands (Martin et al., 2007; Middleton et al., 2008; Moesta et al., 
2008).  
 
Human Leukocyte Antigens 
Human leukocyte antigens (HLA) are highly polymorphic glycoproteins and are 
normally constitutively expressed on all nucleated cells in the body. HLA molecules present self 
and non-self-peptides to T cells. HLA-class I molecules are further divided up into classical 
(HLA-A, -B, -C) and non-classical molecules (HLA-E, -F, -G, UL16-binding proteins (ULBP) 
molecules, and major histocompatibility complex class I-related chain (MIC) A, MICB). HLA-
class I classical molecules are the ligands for KIRs expressed on both NK cells and T cells 
(Leone 2017 KIR-HLA). NKG2A (inhibitory) and NKG2C (activating) NK cell receptors both 
interact with HLA-E. KIRs recognize the HLA-I binding groups HLA Bw4, C1 and C2. Like 
KIR, HLA also has allelic diversity. Various HLA alleles have varying binding affinity for KIR 
and have varying expression levels (Marra et al., 2015).  
 
Tumor response 
NK cells mount a cytolytic response against numerous tumor types (Aquino-Lopez et 
al., 2017). Tumor cells are most sensitive to NK cell lysis when the tumor cells have down-
regulated HLA-I molecules and have upregulated stress-ligands. Tumor cells downregulate 
HLA-I as a way to escape T cell killing, however once HLA is downregulated tumor cells 
become susceptible to NK cell killing (Ljunggren and Karre, 1985; Marin et al., 2003; Demanet 
et al., 2004; Lanier, 2008; Aquino-Lopez et al., 2017). The importance of NK cells for tumor 
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surveillance has been demonstrated in patients who are deficient in NK cells by having an 
increased incidence of various cancers (Orange, 2013). Murine tumor studies have shown that 
the absence or depletion of NK cells leads to increased tumor growth and metastasis (Kim et al., 
2000; Hayakawa et al., 2002; Wu and Lanier, 2003; Hayakawa and Smyth, 2006). Autologous 
and allogeneic NK cells are currently used in the clinical setting for the treatment of leukemia 
and other cancers (Burns et al., 2003; Miller et al., 2005; Romee et al., 2016).  
 
Viral response 
NK cells elicit a potent effector response against virally infected cells and play an important 
role in viral clearance. Viral defense by NK cells is particularly important during hematopoietic 
stem cell transplant (HSCT). NK cells are the first lymphocytes to appear after HSCT and are 
critical for protecting patients against viral infections and tumor reoccurrence post-transplant. 
Post-transplant, patients are highly susceptible to viral infections, the role of NK cells is 
extremely important to protect patients from viruses that can be lethal with a compromised 
immune system. Post-transplant NK cells help mediate graft versus leukemia effect as well as 
aiding in protection against graft versus host disease, which can be life threatening.  
 
1.2 NK cell Education 
NK cell education is an important developmental process that adjusts the alertness of NK 
cells to become functionally competent. NK cell functional competency is defined here by the 
ability to elicit a potent and quick cytokine or cytolytic response. This educational process also 
called licensing is dependent upon the host environment (Kim et al., 2005; Anfossi et al., 2006; 
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Raulet, 2006). NK cell education or licensing is important for NK cell function. In mice, 
unlicensed NK cells are insufficient at viral sensing and viral clearance (Wei et al., 2014).  
NK cells become licensed when the inhibitory KIR on an NK cell interacts with the 
corresponding self-HLA ligand either on the NK cell itself (cis) or a bone marrow derived cell 
(trans) during development (Bessoles et al., 2013; Ebihara et al., 2013). NK cell education is 
critical for effector NK cells to have heightened sensitivity against targets that have down-
regulated HLA. The well-characterized inhibitory KIR that contribute to NK cell education are 
KIR2DL1, KIR2DL2/3 and KIR3DL1 and they interact specifically with HLA C2, HLA C1 and 
HLA Bw4 ligands, respectively. Diversity also exists on the ligand level for NK cells because 
every individual can inherit HLA C1, HLA C2, HLA Bw4 and HLA Bw6 (for which there is no 
known inhibitory KIR) and various combinations of the four. This means that in some 
individuals, NK cells expressing KIR may be unlicensed if their corresponding self-ligand is not 
present, leaving those unlicensed NK cells hypo responsive to targets missing HLA. In the 
cancer setting if an NK cell is unlicensed, even when the tumor cell is missing the self-HLA 
ligand, unlicensed NK cells will be hypo responsive (Fernandez et al., 2005). 
 
There are multiple proposed mechanisms that might explain NK cell education, the ones 
focused on here are the arming model, disarming model and the tuning model.  
 
Arming model 
The ‘Arming Model’ proposes that NK cells are initially hypo-responsive and require 
the interaction between KIR and HLA to acquire functional competency (Kim et al., 2005). In 
this model, KIR ligation with HLA induces inhibitory signaling and causes the phosphorylation 
of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) leading to recruitment and 
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activation of the SH2-domain-containing protein tyrosine phosphatase 1 (SHP1). Through an 
unknown mechanism this inhibitory pathway leads to a heightened cytolytic response in the 
licensed NK cells against targets that lack HLA. Evidence for this model is supported by murine 
studies that have observed that NK specific deletion of ITIMs or SHP1 have hypo-responsive 
and uneducated NK cells (Kim et al., 2005; Wahle et al., 2007; Viant et al., 2014). Adoptive 
transfer of murine mature unlicensed NK cells into a licensing NK cell host showed gain of 
function in the previously unlicensed NK cells, after as few as 7 days post adoptive transfer 
(Elliott et al., 2010). This finding suggests that licensing is plastic and that KIR-HLA interaction 
“arms” the NK cell cytolytic response.   
 
Disarming model 
 The “Disarming Model” proposes that NK cells have heightened effector potential, 
without needing an arming signal, and through overstimulation by activating receptors without 
inhibitory signals to counteract and balance the NK cell response, NK cells become “disarmed” 
and hypo-responsive (Raulet, 2004; Fernandez et al., 2005; Raulet, 2006). Support from this 
model comes from studies observing that continued engagement of activating receptors with 
their ligands in vivo and in vitro leads to NK cell hypo-responsiveness (Oppenheim et al., 2005; 
Coudert et al., 2008; Tripathy et al., 2008; He and Tian, 2017). Additionally, the sustained 
engagement of the activating receptor KIR2DS1 leads to reduced NK cell responsiveness 
(Fauriat et al., 2010; He and Tian, 2017).  
 
Rheostat/Tuning model 
The “Rheostat Model” proposes that NK cell responsiveness is dependent on the 
strength of inhibitory signals received by MHC-I (Brodin et al., 2009; Brodin et al., 2009; 
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Joncker et al., 2009; Kadri et al., 2016). This model also proposes that NK cell responses are 
constantly being tuned in mature NK cells by adjusting to their environment (Brodin et al., 
2009; Brodin et al., 2010; Hoglund and Brodin, 2010; Kadri et al., 2016). Evidence for the 
“Rheostat Model” is supported by mouse and human studies showing that the number of self-
MHC-I receptors, Ly-49 and KIR in mice and humans respectively, is positively correlated with 
increased NK cell responsiveness (Brodin et al., 2009; Joncker et al., 2009; Sleiman et al., 
2014). The more educated inhibitory receptors present on the NK cell, the greater the NK cell 
effector response was observed. However, other studies in humans have also shown that there is 
no correlation between the quantity of self-KIR expression on the NK cell and NK cell 
responsiveness (Charoudeh et al., 2012; Beziat et al., 2013).   Further studies have investigated 
MHC-I expression levels in vitro and in vivo and whether or not MHC-I expression levels can 
tune the NK cell response depending on availability and quantity of MHC-I levels. However, 
several groups have obtained opposing findings, one group found that either low or normal 
expression of MHC-I leads to equal NK cell education, however another group reported that 
expression levels of MHC-I does matter and that lower levels of MHC-I leads to NK cells 
exhibiting lower responsiveness (Jonsson et al., 2010; Brodin et al., 2012).  Due to opposing 
findings in support of or against the “Rheostat Model,” it is difficult to draw conclusions on 
whether or not this model holds up as NK cells undergo education in vivo. Further studies are 
needed to determine the validity of this model. 
 
Non-classical MHC and MHC independent education. 
 In addition to classical MHC education from HLA and KIR interaction, there are 
observations of NK cell education and tuning of responses by inhibitory receptors that interact 
with non-classical MHC and MHC independent ligands for NK cell education. Human NK cell 
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inhibitory receptors that are reported to contribute to NK cell responsiveness include NKG2A, 
TIGIT, 2B4 and interact with the ligands HLA-E, polio virus receptor CD155, and signaling 
lymphocyte activation molecule (SLAM)-related ligand CD48, respectively. For my 
dissertation, I am focusing on the contribution of human KIR receptors and their contribution to 
human NK cell education.  
  
The standard approach for studying human NK cell education is using freshly isolated NK 
cells from the peripheral blood of donors for which HLA and KIR haplotypes are known. 
However, the median NK cell content in peripheral blood is only 1.26 x 10^5 NK cells/mL 
(Pittari et al., 2013), so that sorting pure populations of licensed and unlicensed NK cells from 
an entire buffy coat produces only 1,000,000, and 300,000 licensed and unlicensed NK cells 
respectively.  Such low numbers make some mechanistic studies on these populations infeasible 
on freshly isolated cells unless apheresis products are used. To overcome this challenge, I 
expanded human NK cells ex vivo using an expansion platform developed in our lab as a way to 
generate large amounts of licensed and unlicensed pure NK cell subsets to perform analysis 
with. 
 
It is important to distinguish which NK cell licensing model holds biological significance 
since the hypo responsiveness of the NK cells could potentially be altered in the case of the 
NK cell “arming” or “rheostat” model.  
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1.3 NK cell Expansion 
Studying human NK cell education and licensed versus unlicensed NK cell populations is 
difficult due to feasibility of studying these populations freshly isolated from the peripheral 
blood. Apheresis is likely the only way to obtain enough cells of each population to study. 
However, the willingness and availability of apheresis donors is quite limited, and further 
limited by having to perform costly HLA and KIR genotyping on many potential apheresis 
donors in order to identify a few suitable donors. NK cell expansion from a small amount of 
peripheral blood is currently used as a way to generate high quantities of NK cells to be used for 
NK cell adoptive therapy (Somanchi et al., 2011; Denman et al., 2012). We had previously 
performed KIR and HLA typing on 25 colleagues who were willing to donate peripheral blood 
for research studies under an IRB approved protocol.   
Table 1: KIR and HLA donor typing 
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I utilized an NK cell expansion platform developed in our lab as a way to generate sufficient 
numbers of licensed and unlicensed NK cell populations to study mechanistic differences 
between the two subsets (Somanchi et al., 2011; Denman et al., 2012). Other methods of NK 
cell expansion have also been used, however the method developed by our laboratory achieved 
expansion of NK cells unmatched by all other NK cell expansion techniques. The expansion 
platform I used involves expanding licensed and unlicensed sorted NK cell populations with the 
Clone9.mbIL21 K562 feeder cell line and low dose IL-2. The feeder cells express 4-1BBL and 
membrane bound IL-21 that aid in activating and propagating the cells ex vivo. This expansion 
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method generates a mean fold expansion of 48,000 with bulk NK cells isolated from the 
peripheral blood (Denman et al., 2012). While this is not the ideal model system to study NK 
cell education due to artificially manipulating the NK cells in vitro, many differences were 
observed in the licensed and unlicensed NK cell signaling pathways between the two subsets 
post ex vivo expansion.  
 
1.4 NK cell Metabolism 
Generating energy is important for cell functions such as proliferation and effector 
functions. There are two major energy-producing pathways glycolysis and mitochondrial 
respiration also known as oxidative phosphorylation (OXPHOS) , that I focused on for my 
dissertation. Glycolysis involves the conversion of intracellular glucose into pyruvate. Pyruvate 
has two major fates: the first is that pyruvate can be further converted into lactate and shuttled 
out of the cell as lactic acid, this is a short and quick way of producing energy and 2 molecules 
of ATP are generated per one glucose molecule. This short and quick way of metabolizing 
glucose into lactic acid is conventionally performed in the absence of oxygen (anaerobic 
conditions), whereas OXPHOS requires oxygen. However, highly proliferative cells such as 
tumor cells and immune cells also undergo glycolysis to produce lactic acid even in the presence 
of oxygen (aerobic), this is called the Warburg effect and was first described by Otto Warburg 
(Warburg et al., 1927; Warburg et al., 1958). In addition to energy aerobic glycolysis can 
generate biosynthetic precursors that facilitate the survival of proliferating cells (Romero-Garcia 
et al., 2016).  The second fate of pyruvate is to be converted into acetyl-coA and shuttled into 
the tricarboxylic acid cycle (TCA). The TCA cycle generates NADH, which is then used in 
OXPHOS to generate 34 ATP molecules in addition to 2 ATP molecules produced from 
glycolysis and 2 ATP molecules produced in the TCA cycle. Traditionally, OXPHOS is able to 
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produce 70-95% of the cells energy (Vander Heiden et al., 2009; Nsiah-Sefaa and McKenzie, 
2016). While OXPHOS is a very efficient metabolic pathway to produce energy, it is also very 
slow. Aerobic glycolysis can be quicker at generating a large amount of ATP than mitochondrial 
respiration.  
 
Several studies in T cells have shown that proliferation is dependent upon glucose 
metabolism (Newsholme et al., 1985; Newsholme et al., 1985; Jacobs et al., 2008; Wang et al., 
2011; van der Windt and Pearce, 2012).  Upon T cell activation, GLUT1glucose transporters are 
up regulated along with an increase in glucose uptake and glycolysis (Frauwirth et al., 2002; 
Jacobs et al., 2008). Few metabolic studies have been performed in NK cells, and only bulk NK 
cell analysis has been possible because of the infrequent numbers of NK cells per subset that 
exist within an individual (Donnelly et al., 2014; Marcais et al., 2014; Marcais and Walzer, 
2014; Keppel et al., 2015). Glycolysis and OXPHOS are critical for murine and bulk human NK 
cell cytokine production (Donnelly et al., 2014; Keppel et al., 2015; Keating et al., 2016). 
Resting NK cells exhibit low levels of OXPHOS and glycolysis (Keppel et al., 2015). One study 
compared human NK cell subsets CD56dim mature NK cells to CD56bright immature NK cells 
and found that the CD56bright NK cells were more metabolically active and have increased 
glucose metabolism compared to the CD56dim NK cells (Keating et al., 2016). In the same 
study, OXPHOS metabolism was found to be important for NK cell cytotoxicity and IFN-γ 
production. Lastly in the CD56bright NK cells glycolysis was a key regulator of IFN- γ production 
as these cells are the main cytokine producers (Keating et al., 2016). 
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1.5 Regulation of Glycolysis  
Glycolysis is a tightly regulated pathway and can be regulated by different proteins in 
various cell types. T cell activation through CD28 signaling leads to PI3K/Akt/mTOR signaling 
cascade, leading to an increase in aerobic glycolysis (Frauwirth et al., 2002). Akt and mTOR 
signaling act to induce glycolysis post-translationally by increasing glucose transporters on the 
cell surface, activating p70S6 kinase leading to the activation of glycolysis and activating 
glycolysis enzymes (Miyamoto et al., 2008; Tandon et al., 2011; Gerriets and Rathmell, 2012). 
AMP-activated protein kinase (AMPK) can act as both an inhibitor and an activator of 
glycolysis. AMPK becomes activated when the ratio of AMP to ATP is high, thus sensing low 
cellular energy levels. In a study of T cell lymphoblastic leukemia, AMPK signaling inhibited 
glycolysis through a mTORC1 dependent manner (Kishton et al., 2016). In a separate study, 
AMPK signaling through activation of PFKFB3, a glycolysis enzyme, acted to increase 
glycolysis leading to survival of breast cancer cell lines (Domenech et al., 2015). Another study 
observed that AMPK signaling leads to activation of glycolysis during mitochondrial stress (Wu 
and Wei, 2012). In one study, AMPK activation occurs after T cell activation via TCR 
stimulation by a Ca2+ -calmodulin-dependent kinase kinase kinase (CAMKK) dependent 
mechanism (Tamas et al., 2006). AMPK signaling can also lead to activation of the glucose 
transporter GLUT1 in a rat liver epithelial cell line (Barnes et al., 2002). The importance of 
AMPK signaling in metabolism lead us to investigate the role of AMPK signaling in NK cell 
glycolysis. 
 
P38, a member of the mitogen activated protein kinase (MAPK) protein family was 
shown to play a role in glycolysis activation and inhibition. P38 in response to stress controls 
transcription of immediate-early genes. In one study, p38 signaling led to a signaling cascade 
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that resulted in PFKFB3 activation leading to an increase in glycolysis (Novellasdemunt et al., 
2013).  
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Chapter 2: Materials and Methods 
Human Subjects 
NK cells were derived from peripheral blood or buffy coats of normal healthy volunteer donors 
under the MD Anderson Cancer Center IRB-approved protocol LAB07-0296 or IRB exemption 
PA13-0978. Donors were selected by KIR and HLA genotyping. Only donors with KIR A 
haplotype were used, to eliminate all activating KIRs from influencing any data. 5 donors were 
used total, and replicates for each donor are described in the figure legends. 
NK Cell Isolation  
NK cells were isolated from both buffy coats and whole blood using the previously described 
method (Somanchi et al., 2011).  Briefly, PBMCs from buffy coat or whole blood diluted with 
PBS at a 2:1 PBS to blood ratio was layered over ficoll hypaque in 50mL conical tubes and 
centrifuged for 20 min at 1200 RPM with no break. PBMCs were collected and washed 2 times 
with PBS. PMBCs were counted and RBCs were added at ratio of 100:1 RBC: WBC. RBCs and 
WBCs were then incubated with Rosette Sep NK cell cocktail for 20 min. Cells were then 
layered over ficoll hypaque in 50mL conical tubes and centrifuged for 20 min at 1200 RPM no 
break. Purified NK cells were then washed 2 times with PBS and RBCs were lysed when 
necessary. Purity of NK cells was assessed by flow cytometry.  
KIR and HLA Typing 
DNA was isolated from NK cells and submitted to the HLA laboratory at the University of 
Texas MD Anderson Cancer Center for HLA and KIR typing. HLA typing was performed at the 
intermediate-resolution level at HLA-A, HLA-B, and HLA-C loci by PCR amplification and 
oligonucleotide hybridization (One Lambda, Canoga Park, CA). KIR genotyping was performed 
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with reverse sequence-specific oligonucleotide methodology using fluorescently labeled beads 
conjugated to oligonucleotide probes (One Lambda). The HLA group for KIR binding was 
determined using the KIR Ligand Calculator maintained by the European Bioinformatics 
Institute of the European Molecular Biology Labs (EMBL-EBI) 
(http://www.ebi.ac.uk/ipd/kir/ligand.html). 
Licensed and Unlicensed NK cell Discrimination 
To avoid confounding from expression of multiple KIRs, here we identified licensed and 
unlicensed NK cells as those expressing a single inhibitory KIR in an individual who has or 
lacks, respectively, the relevant cognate We selected the following KIR AA haplotype available 
individuals from table 1; donors 13, 18, and 19. Donors 8 and 5 were also used for preliminary 
experiments. HLA ligand and lacks a complementary activating KIR (e.g., 
KIR2DL1+KIR2DL2/3−KIR3DL1− NK cells in an HLA-C*0201 individual who lacks the 
KIR2DS1 gene). Licensed status was determined irrespective of NKG2A expression. 
Flow Cytometry 
NK cells were labeled with fluorescently conjugated human antibodies to determine licensed 
and unlicensed NK cell populations: CD56 PerCP CY5.5 (Biolegend), CD3 APC Cy7 
(Biolegend), KIR2DL1 FITC (R&D), KIR2DL2/3 APC (Miltenyi), and KIR3DL1 PE 
(Beckman Coulter). Cells were stained with antibodies at concentrations according to 
manufacturer guidelines and titrated when necessary. For intracellular staining, cells were 
washed with staining buffer containing phosphate buffered saline (PBS) and 5% fetal bovine 
serum (FBS). Cells were fixed in 2% formaldehyde for 10 minutes, then washed and 
permeablized with methanol on ice for 10 minutes. NK cells were then washed with staining 
buffer, followed by staining for p-38 MAPK (D13E1) antibody (Cell Signaling Technologies). 
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Flow cytometry was performed on an LSR Fortessa (BD Biosciences).  
Cell Sorting 
Cells were labeled with the following fluorescently conjugated human antibodies: CD56 PerCP 
CY5.5 (Biolegend), CD3 APC Cy7 (Biolegend), KIR2DL1 FITC (R&D), KIR2DL2/3 APC 
(Miltenyi), and KIR3DL1 PE (Beckman Coulter). Cells were stained with antibodies at 
concentrations according to manufacturer guidelines and titrated when necessary. Cells were 
sorted using a FACSAria IIu sorter (BD Biosciences).  
Cell Expansion 
Each NK cell population positive for a single KIR were expanded in the presence of K562 
Clone9.mbIL21 artificial activating and propagating cells for 14-21 days as previously 
described (Denman et al., 2012). Cells were counted using a hemocytometer. Briefly, purified 
NK cell populations were expanded for 7 days with a 2:1 K562 Clone9.mbIL21feededer cell: 
NK cell ratio. Fresh IL-2 at 50 IU/mL was added every other day along with fresh media.	
721.221 cell line was used in the expansion of bulk NK cells from typed donors to determine the 
percentages of licensed and unlicensed NK cells before and after expansion. 
Cell Culture 
Mononuclear cells from peripheral blood were cultured in RPMI 1640 Medium supplemented 
with 50 IU/mL recombinant human IL-2, 10% FBS, L-glutamine, and penicillin/streptomycin, 
as previously described (Denman et al., 2012). The medium was changed every other day. 
Cytotoxicity Assays 
Frozen PBMCs or expanded NK cells were thawed two days prior to effector assays. 
CalceinAM was used to measure cytotoxicity as previously described(Somanchi et al., 2011). 
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Effector target ratios are described in figure legends. Briefly, 721.221 cells were loaded with 
calcein for 1hr. 721.221 calcein loaded target cells were incubated with NK cells at varying 
effector target ratios for 4-6 hours as indicated in figure legends.  
Metabolic Inhibitors 
The following metabolic inhibitors were used during cytotoxicity assays and expansion 
protocols as indicated: 500µM AICAR, 5µM shikonin, 2mM 2-DG, and 40nM oligomycin (all 
from Sigma). Glucose-free medium was made using glucose-free RPMI supplemented with 
10% dialyzed FBS, 50 IU/mL recombinant human IL-2, L-glutamine, and 
penicillin/streptomycin. 
Mass Cytometry 
Frozen primary PBMCs (for Telo-FISH) and expanded NK cells (for phospho-CyTOF staining) 
were thawed 2 days prior to staining to allow for cell recovery. Antibodies were labeled with 
heavy metals using Maxpar-X8 labeling reagent kits (DVS Sciences) according to the 
manufacturer’s instructions and were titrated to determine the optimal concentration. Live cell 
discrimination was performed by washing cells twice in serum-free medium for 5 minutes at 
500 × g. Cells were then labeled with 5 µM cisplatin for 1 minute followed by two washes in 
complete medium for 5 minutes at 500 × g. Cells were stained as previously described, and data 
were acquired on a CyTOF instrument (DVS Sciences; (Bendall et al., 2011)). The antibody 
clones and their respective heavy metal are in Table 1.  
Telofish with CyTOF 
PBMCs were first stained for live cell discrimination with 5uM cisplatin in serum free RMPI 
media for 1 minute. Cells were then washed and incubated with Fc blocker for ten minutes and 
then stained for surface receptors. Next cells were fixed with 2% formaldehyde for ten minutes 
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at room temperature. Cells were then permeabilized with methanol for ten minutes on ice. 
Intracellular staining was then performed for 30 minutes. Cells were then crosslinked by BS3  
(Thermo scientific) 200uL of 10mM BS3 solution added drop wise to cell pellet and incubated at 
4oC for 30 minutes (Schmid and Jamieson, 2004). 20uL of 1M TrisCl, pH 8.0 was added to the 
cell solution, mixed well and incubated at room temperature for 30 minutes. Cells were washed 
with PBS and centrifuged 500 g for 5 minutes. Cells were resuspended in PBS and counted 
using a hemocytometer. Cells were centrifuged at 500 g for 5 minutes in 500uL of PBS 
containing 2% BSA in a 1.5mL eppendorf tube. 500uL of deionized formamide was added to 
the cell suspension and mixed gently by pipetting. Cells were incubated for ten minutes at room 
temperature, fifteen minutes at 87oC and then ten minutes at room temperature. Cells were 
centrifuged and washed two times with 2% BSA in PBS. After the final spin, supernatant was 
removed and 2% BSA in PBS containing 2.5nM PNA probe Cy5-OO-(CCCTAA)3  in ratio of 
100uL per one million cells was added. Cells were incubated overnight at room temperature in 
the dark with gentle rotation. Cells were washed twice with 2% BSA in PBS. Cells were stained 
with an anti-Cy5 metal conjugated antibody (same as intracellular staining above). Cells were 
then stained with Ir intercalator after intracellular staining as previously described (Bendall et 
al., 2011).  
Extracellular Flux Assays 
All reagents were from Agilent Technologies unless otherwise stated. Mito stress and glycolysis 
stress tests were performed to measure extracellular acidification rate (ECAR) and oxygen 
consumption rate (OCR) using the Seahorse XFe96 analyzer. NK cells were seeded (300,000 
cells per well) on 96-well flux plates coated with Cell-Tak (Corning) according to manufacturer 
guidelines. Glycolysis was determined in the presence of saturating amounts of glucose in the 
glycolysis stress test. Glycolytic Capacity is the maximum glycolytic rate after mitochondrial 
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respiration is inhibited in the mitochondrial stress test. Glycolytic reserve represents the 
maximum glycolytic function of a cell and equals Glycolytic Capacity - Glycolysis (Agilent 
Technologies). NK cells were assayed in triplicate in XF Base Medium at pH of 7.35. For the 
glycolysis stress test, NK cells were supplemented with 2 mM glutamine, 10 mM glucose, 1 µM 
oligomycin, and 50 mM 2-DG. For the mitochondrial stress test, XF Base Medium was 
supplemented with 25 mM glucose, 1 mM pyruvate, and 2 mM glutamine, and the following 
drug concentrations were used: 1 µM oligomycin, 1.5 µM FCCP, and 0.5 µM rotenone and 
Antimycin A.  
siRNA Knockdown 
Expanded licensed NK cells were subjected to siRNA knockdown using ON-TARGETplus 
Non-Targeting Pool, ON-TARGETplus human MAPK14 siRNA, ON-TARGETplus PRKAA1 
siRNA and ON-TARGETplus PRKAA2 (all from Dharmacon). siRNA knockdown was 
performed using a Human NK Cell Nucleofector Kit (Lonza) by electroporation with an Amaxa 
Nucleofector Device as previously described (Phatarpekar et al., 2016). 
Cross-linking NK Cells for Protein Expression Analysis 
1x107 cells were used for cross-linking experiments. Cells were washed in NK cell medium 
containing 10% FBS for blocking. NK cells were incubated for 30 minutes on ice with the 
primary antibody at a concentration of 10µg/mL. Cells were then washed twice. To cross-link 
the cells, the secondary antibody was added at a concentration of 1µg/mL for 10 min at 37°C. 
Cells were then pelleted for protein lysate purification. Primary antibodies include: KIR3DL1 
(BD Bioscience), KIR2DL1 (Biolegend), KIR2DL2/3 (Biolegend), human NKp46 (Biolegend). 
Isotype control antibody was Mouse IgG1 (Tonbo).  Secondary antibody was goat-anti-mouse 
IgG (Biolegend).  
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Table 1: Telofish and phospho-CyTOF antibody panel. 
Marker Metal or 
Fluorophore 
clone source Catalog # 
Idu I127Di   Sigma I7125-5G 
PE* 141Pr PE001 BioLegend 408102 
CD19 Nd142Di HIB19 BioLegend 302202 
FITC* 144Nd FIT-22 DVS-Fluidigm 3144006B 
CD4 Nd145 RPA-T4 BioLegend 300502 
CD8a Nd146Di RPA-T8 BioLegend 301002 
CD20 Sm147Di 2H7 DVS-Fluidigm 3147001B 
CD45RA Eu153 HI100 DVS-Fluidigm 3153001B 
CD45 Sm154Di HI30 DVS-Fluidigm 3154001B 
CD33 Gd158Di WM53 DVS-Fluidigm 3158001B 
Cy5 Tb159Di CY5-15 Abcam ab52061 
CD14 Gd160Di M5E2 DVS-Fluidigm 3160001B 
p-p38 (180/182) 160Dd D3F9 CST 4511BF 
NKp80 161Dy 5D12 BioLegend 346702 
CD56 Dy162Di NCAM16.2 BD 559043 
p-AMPK (T172) 164Dy 40H9 CST 2535BF 
CD16 Ho165Di 3G8 DVS-Fluidigm 3165001B 
NKG2A 166Er 131411 R&D MAB1059 
NKG2C 169Tm 134522 R&D MAB1381 
APC* 170Er A85-1 BD 560089 
CD62L Tb171Di DREG-56 BioLegend 304802 
CD57 Yb172Di HCD57 DVS-Fluidigm 3712009B 
CD3 Lu175Di UCHT1 BioLegend 300443 
CyclinB1 Yb176Di GNS-1 BD 554177 
CD45 QDOT655 HI30 Thermo Fisher 
Scientific 
Q22154 
KIR3DL/DS1 PE Z27.3.7 Beckman 
Coulter 
41116015 
KIR2DL1 FITC 143211 R&D FAB1844F 
KIR2DL2/DL3 APC DX27 Miltenyi 130-092-617 
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Reverse Phase Protein Array 
Cells were first expanded for 3 weeks, as described above. A reverse phase protein array was 
performed by the University of Texas MD Anderson Cancer Center RPPA core. In brief, NK 
cell lysates were serially diluted two-fold, five times, and arrayed on nitrocellulose-coated 
slides. Samples were probed with antibodies using a tyramide-based signal amplification 
approach and were visualized using the diaminobenzidine colorimetric reaction. Slides were 
scanned on a flatbed scanner to produce a 16-bit tiff image. Spots from the images were 
identified, and the optical density was quantified with an Array-Pro Analyzer 
(MeidaCybernetics, Rockville, Maryland). Relative protein levels for each sample were 
determined by interpolation of each dilution curve from the “standard curve” (SuperCurve) of 
the slide (antibody). The SuperCurve was constructed by a script in R. All data points were 
normalized for protein loading and transformed to linear values and then to log2 values.  
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Table 2: Reverse phase protein array antibody Panel. 
#	 Official	Ab	Name		 Ab	Name	Reported	on	
Dataset	
Gene	Name	 Company	 Catalog	#	
1	 14-3-3	beta	 14-3-3-beta	 YWHAB	 Santa	Cruz	 sc-628	
2	 14-3-3	epsilon	 14-3-3-epsilon	 YWHAE	 Santa	Cruz	 sc-23957	
3	 14-3-3	zeta	 14-3-3-zeta	 YWHAZ	 Santa	Cruz	 sc-1019	
4	 4E-BP1	 4E-BP1	 EIF4EBP1	 CST	 9452	
5	 4E-BP1	(phospho	S65)	 4E-BP1_pS65	 EIF4EBP1	 CST	 9456	
6	 4E-BP1	(phospho	T37/T46)	 4E-BP1_pT37_T46	 EIF4EBP1	 CST	 9459	
7	 53BP1	 53BP1	 TP53BP1	 CST	 4937	
8	 Acetyl	CoA	Carboxylase	(phospho	S79)	 ACC_pS79	 ACACA,	ACACB	 CST	 3661	
9	 Acetyl	CoA	Carboxylase	1	 ACC1	 ACACA	 Abcam	 ab45174	
10	 ACVRL1	 ACVRL1	 ACVRL1	 Abcam	 ab108207	
11	 ADAR1	 ADAR1	 ADAR	 Abcam	 ab88574	
12	 Akt	 Akt	 AKT1,2,3	 CST	 4691	
13	 Akt	(phospho	S473)	 Akt_pS473	 AKT1,2,3	 CST	 9271	
14	 Akt	(phospho	T308)	 Akt_pT308	 AKT1,2,3	 CST	 2965	
15	 AMPK	alpha	 AMPKa	 PRKAA1	 CST	 2532	
16	 AMPK	alpha	(phospho	T172)	 AMPKa_pT172	 PRKAA1	 CST	 2535	
17	 Androgen	Receptor	 AR	 AR	 Abcam	 ab52615	
18	 Annexin	I	 Annexin-I	 ANXA1	 BD	Biosciences	 610066	
19	 Annexin	VII	 Annexin-VII	 ANXA7		 BD	Biosciences	 610668	
20	 A-Raf	 A-Raf	 ARAF	 CST	 4432	
21	 ARHI	 ARHI	 DIRAS3	 MDACC	Laboratory	 Bast	Lab	
22	 ARID1A	 ARID1A	 ARID1A	 Sigma-Aldrich	 HPA005456	
23	 Atg3	 Atg3	 ATG3	 CST	 3415	
24	 Atg7	 Atg7	 ATG7	 CST	 8558	
25	 ATM	 ATM	 ATM	 CST	 2873	
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26	 ATM	(phospho	S1981)	 ATM_pS1981	 ATM	 CST	 5883	
27	 ATP5A	 ATP5A	 ATP5A	 Abcam	 ab14748	
28	 ATR	(Phospho	S428)	 ATR_pS428	 ATR	 Abcam	 ab178407	
29	 Aurora	B/AIM1	 Aurora-B	 AIM1	 CST	 3094	
30	 Axl	 Axl	 AXL	 CST	 8661	
31	 B7-H3	 B7-H3	 CD276	 CST	 14058	
32	 B7-H4	 B7-H4	 VTCN1	 CST	 14572	
33	 Bad	(phospho	S112)	 Bad_pS112	 BAD	 CST	 9291	
34	 Bak	 Bak	 BAK1	 Abcam	 ab32371	
35	 BAP1	 BAP1	 BAP1	 Santa	Cruz	 sc-28383	
36	 Bax	 Bax	 BAX	 CST	 2772	
37	 Bcl2	 Bcl2	 BCL2	 Dako	 M0887	
38	 Bcl2A1	 Bcl2A1	 BCL2A1	 Abnova	 PAB8528	
39	 Bcl-xL	 Bcl-xL	 BCL2L1	 CST	 2762	
40	 Beclin	 Beclin	 BECN1	 Santa	Cruz	 sc-10086	
41	 beta	Actin	 b-Actin	 ACTB	 CST	 4970	
42	 beta	Catenin	 b-Catenin	 CTNNB1	 CST	 9562	
43	 beta	Catenin	(phospho	T41/S45)	 b-Catenin_pT41_S45	 CTNNB1	 CST	 9565	
44	 Bid	 Bid	 BID	 Abcam	 ab32060	
45	 Bim	 Bim	 BCL2L11	 Abcam	 ab32158	
46	 B-Raf	 B-Raf	 BRAF	 Abcam	 ab33899	
47	 B-Raf	(phospho	S445)	 B-Raf_pS445	 BRAF	 CST	 2696	
48	 BRD4	 BRD4	 BRD4	 CST	 13440	
49	 c-Abl	 c-Abl	 ABL	 CST	 2862	
50	 Caspase-3	active	 Caspase-3	 CASP3	 Abcam	 ab32042	
51	 Caspase-7	(cleaved	D198)	 Caspase-7-cleaved	 CASP7	 CST	 9491	
52	 Caspase-8	 Caspase-8	 CASP8	 CST	 9746	
53	 Caveolin-1	 Caveolin-1	 CAV1	 CST	 3238	
54	 CD171	(L1)	 CD171	 L1CAM	 BioLegend	 826701	
55	 CD26	 CD26	 CD26	 Abcam	 ab28340	
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56	 CD29	 CD29	 ITGB1	 BD	Biosciences	 610467	
57	 CD31	 CD31	 PECAM1	 Dako	 M0823	
58	 CD44	 CD44	 CD44	 CST	 3570	
59	 CD49b	 CD49b	 ITGA2	 BD	Biosciences	 611016	
60	 cdc25C	 cdc25C	 CDC25C	 CST	 4688	
61	 CDK1	 CDK1	 CDK1	 Abcam	 ab32384	
62	 CDKN2A/p16INK4a	 p16INK4a	 CDKN2A	 Abcam	 ab81278	
63	 Chk1	 Chk1	 CHEK1	 CST	 2360	
64	 Chk1	(phospho	S296)	 Chk1_pS296	 CHEK1	 Abcam	 ab79758	
65	 Chk1	(phospho	S345)	 Chk1_pS345	 CHEK1	 CST	 2348	
66	 Chk2	 Chk2	 CHEK2	 CST	 3440	
67	 Chk2	(phospho	T68)	 Chk2_pT68	 CHEK2	 CST	 2197	
68	 c-Jun	(	phospho	S73)	 c-Jun_pS73	 JUN	 CST	 9164	
69	 c-Kit	 c-Kit	 KIT	 Abcam	 ab32363	
70	 Claudin	7	 Claudin-7	 CLDN7	 Novus	Biologicals	 NB100-91714	
71	 c-Met	 c-Met	 MET	 CST	 3127	
72	 c-Met	(phospho	Y1234/Y1235)	 c-Met_pY1234_Y1235	 MET	 CST	 3129	
73	 c-Myc	 c-Myc	 MYC	 Santa	Cruz	 sc-764	
74	 COG3	 COG3	 COG3	 ProteinTech	 11130-1-AP	
75	 COL6A1	 Collagen-VI	 COL6A1	 Santa	Cruz	 sc-20649	
76	 Complex	II	Subunit	 Complex-II-Subunit	 SDHB	 Invitrogen	 459230	
77	 Connexin	43	 Connexin-43	 CNST43	 CST	 3512	
78	 Coup-TFII	 Coup-TFII	 NR2F2	 CST	 6434	
79	 Cox	IV	 Cox-IV	 COX4I1	 Abcam	 ab14744	
80	 Cox2	 Cox2	 PTGS2	 CST	 4842	
81	 C-Raf	(phospho	S338)	 C-Raf_pS338	 RAF1	 CST	 9427	
82	 C-Raf/Raf-1	 C-Raf	 RAF1	 Millipore	 04-739	
83	 CXCR4	 CXCR4	 CXCR4	 Abcam	 ab2074	
84	 Cyclin	B1	 Cyclin-B1	 CCNB1	 Epitomics	 1495-1	
85	 Cyclin	D1	 Cyclin-D1	 CCND1	 Santa	Cruz	 sc-718	
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86	 Cyclin	E1	 Cyclin-E1	 CCNE1	 Santa	Cruz	 sc-247	
87	 Cyclophilin	F	 Cyclophilin-F	 PPIF	 Abcam	 ab110324	
88	 Cytokeratin	19	 Cytokeratin-19	 KRT19	 Dako	 M0888	
89	 Detyrosinated	alpha-Tubulin	 D-a-Tubulin	 TUBA1A	 Abcam	 ab48389	
90	 Dimethyl-Histone	H3	(Lys4)	 DM-Histone-H3	 HISTH3	 Millipore	 07-030	
91	 Dimethyl-K9	Histone	H3	 DM-K9-Histone-H3	 H3K9ME2	 Abcam	 ab32521	
92	 DUSP4/MKP2	 DUSP4	 DUSP4	 CST	 5149	
93	 Dvl3	 Dvl3	 DVL3	 CST	 3218	
94	 E2F-1	 E2F1	 E2F1	 Santa	Cruz	 sc-251	
95	 E-Cadherin	 E-Cadherin	 CDH1	 CST	 3195	
96	 eEF2	 eEF2	 EEF2	 CST	 2332	
97	 eEF2K	 eEF2K	 EEF2K	 CST	 3692	
98	 EGFR	 EGFR	 EGFR	 CST	 2232	
99	 EGFR	(phospho	Y1068)	 EGFR_pY1068	 EGFR	 CST	 2234	
100	 EGFR	(phospho	Y1173)	 EGFR_pY1173	 EGFR	 Abcam	 ab32578	
101	 eIF4E	 eIF4E	 EIF4E	 CST	 9742	
102	 eIF4G	 eIF4G	 EIF4G1	 CST	 2498	
103	 Elk1	(phospho	S383)	 Elk1_pS383	 ELK1	 CST	 9181	
104	 Epithelial	Membrane	Antigen	 EMA	 EMA	 Dako	 M061329-2	
105	 ErbB2/HER2	 HER2	 ERBB2	 Lab	Vision	 MS-325-P1	
106	 ErbB2/HER2	(phospho	Y1248)	 HER2_pY1248	 ERBB2	 R&D	Systems	 AF1768	
107	 ErbB3/HER3			 HER3	 ERBB3	 Santa	Cruz	 sc-285	
108	 ErbB3/HER3	(phospho	Y1289)	 HER3_pY1289	 ERBB3	 CST	 4791	
109	 ERCC1	 ERCC1	 ERCC1	 Santa	Cruz	 sc-17809	
110	 ERCC5	 ERCC5	 ERCC5	 ProteinTech	 11331-1-AP	
111	 ERRFI1/MIG6	 MIG6	 ERRFI1	 Sigma-Aldrich	 WH0054206M1	
112	 Estrogen	Receptor	 ER	 ESR1	 Lab	Vision	 RM-9101	
113	 Ets-1	 Ets-1	 ETS1	 Bethyl	 A303-501A	
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114	 FAK		 FAK	 PTK2	 Abcam	 ab40794	
115	 FAK	(phospho	Y397)	 FAK_pY397	 PTK2	 CST	 3283	
116	 Fatty	Acid	Synthase	 FASN	 FASN	 CST	 3180	
117	 Fibronectin	 Fibronectin	 FN1	 Epitomics	 1574-1	
118	 FoxM1	 FoxM1	 FOXM1	 CST	 5436	
119	 FoxO3a	 FoxO3a	 FOXO3	 CST	 2497	
120	 FoxO3a	(phospho	S318/S321)	 FoxO3a_pS318_S321	 FOXO3	 CST	 9465	
121	 FRA-1	 FRA-1	 FRA1	 Santa	Cruz	 sc-605	
122	 G6PD	 G6PD	 G6PD	 Santa	Cruz	 sc-373887	
123	 Gab2	 Gab2	 GAB2	 CST	 3239	
124	 GAPDH	 GAPDH	 GAPDH	 Life	Technologies	 AM4300	
125	 GATA3	 GATA3	 GATA3	 BD	Biosciences	 558686	
126	 GCN5L2	 GCN5L2	 KAT2A	 CST	 3305	
127	 Glutamate	Dehydrogenase1/2	 Glutamate-D1-2	 GLUD	 CST	 12793	
128	 Glutaminase	 Glutaminase	 GLS	 Abcam	 ab156876	
129	 Glycogen	Synthase	 Gys	 GYS1	 CST	 3886	
130	 Glycogen	Synthase	(phospho	S641)	 Gys_pS641	 GYS1	 CST	 3891	
131	 GPBB	 GPBB	 PYGB	 Novus	Biologicals	 NBP1-32799	
132	 GSK-3alpha/beta	 GSK-3a-b	 GSK3A,	GSK3B	 Santa	Cruz	 sc-7291	
133	 GSK-3alpha/beta	(phospho	S21/S9)	 GSK-3a-b_pS21_S9	 GSK3A,	GSK3B	 CST	 9331	
134	 H2AX	(phospho	S140)	 H2AX_pS140	 H2AX	 Pierce	Biotechnology	 MA1-2022	
135	 Heregulin	 Heregulin	 NRG1	 CST	 2573	
136	 HES1	 HES1	 HES1	 CST	 11988	
137	 Hexokinase	II	 Hexokinase-II	 HK2	 CST	 2867	
138	 HIAP	 HIAP	 BIRC2		 Millipore	 07-759	
139	 Hif-1	alpha	 Hif-1-alpha	 HIF1A	 BD	Biosciences	 610958	
140	 Histone	H3	 Histone-H3	 H3F3A,	H3F3B	 Abcam	 ab1791	
141	 HSP27	 HSP27	 HSP27	 CST	 2402	
142	 HSP27	(phospho	S82)	 HSP27_pS82	 HSBP1	 CST	 2401	
143	 HSP70	 HSP70	 HSP70	 CST	 4872	
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144	 IGF1R	(phospho	Y1135/Y1136)	 IGF1R_pY1135_Y1136	 IGF1R	 CST	 3024	
145	 IGFBP2	 IGFBP2	 IGFBP2	 CST	 3922	
146	 IGFBP5	 IGFBP5	 IGFBP5	 Santa	Cruz	 sc-6006	
147	 IGFRb	 IGFRb	 INSR	 CST	 3027	
148	 INPP4b	 INPP4b	 INPP4B	 CST	 4039	
149	 IRF-1	 IRF-1	 IRF1	 Santa	Cruz	 sc-497	
150	 IRS1	 IRS1	 IRS1	 Millipore	 06-248	
151	 JAB1	 JAB1	 COPS5	 Santa	Cruz	 sc-13157	
152	 Jagged1	 Jagged1	 JAG1	 Abcam	 ab109536	
153	 Jak2	 Jak2	 JAK2	 CST	 3230	
154	 JNK/SAPK	(phospho	T183/Y185)	 JNK_pT183_Y185	 MAPK8	 CST	 4668	
155	 JNK2	 JNK2	 MAPK9	 CST	 4672	
156	 LC3A/B	 LC3A-B	 LC3AB	 CST	 4108	
157	 Lck	 Lck	 LCK	 CST	 2752	
158	 LDHA	 LDHA	 LDHA	 CST	 3582	
159	 MAPK	(phospho	T202/Y204)	 MAPK_pT202_Y204	 MAPK1,	MAPK3	 CST	 4377	
160	 Mcl	1	 Mcl-1	 MCL1	 CST	 5453	
161	 MDM2	(phospho	S166)	 MDM2_pS166	 MDM2	 CST	 3521	
162	 MEK1	 MEK1	 MAP2K1	 Epitomics	 1235-1	
163	 MEK1	(phospho	S217/S221)	 MEK1_pS217_S221	 MAP2K1	
MAP2K2	
CST	 9154	
164	 MEK2	 MEK2	 MAP2K2	 CST	 9125	
165	 Merlin/NF2	 Merlin	 NF2	 Novus	Biologicals	 22710002	
166	 MIF	 MIF	 MIF	 Santa	Cruz	 sc-20121	
167	 Mitochondria	 Mitochondria	 MTCO2	 Abcam	 ab3298	
168	 MMP2	 MMP2	 MMP2	 CST	 4022	
169	 Mnk1	 Mnk1	 MKNK1	 CST	 2195	
170	 Monocarboxylic	Acid	Transporter	4	 MCT4	 SLC16A4	 Millipore	 AB3314P	
171	 MSH2	 MSH2	 MSH2	 CST	 2850	
172	 MSH6	 MSH6	 MSH6	 Novus	Biologicals	 22030002	
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173	 mTOR	 mTOR	 MTOR	 CST	 2983	
174	 mTOR	(phospho	S2448)	 mTOR_pS2448	 MTOR	 CST	 2971	
175	 Myosin	heavy	chain	11	 Myosin-11	 MYH11	 Novus	Biologicals	 21370002	
176	 Myosin	IIa	(phospho	S1943)	 Myosin-IIa_pS1943	 MYH9	 CST	 5026	
177	 Myt1	 Myt1	 MYT1	 CST	 4282	
178	 NAPSIN	A	 NAPSIN-A	 NAPSA	 Abcam	 ab129189	
179	 N-Cadherin	 N-Cadherin	 CDH2	 CST	 4061	
180	 NDRG1	(phospho	T346)	 NDRG1_pT346	 NDRG1	 CST	 3217	
181	 NDUFB4	 NDUFB4	 NDUFB4	 Abcam	 ab110243	
182	 NF-kappaB	p65	(phospho	S536)	 NF-kB-p65_pS536	 RELA	 CST	 3033	
183	 Notch1	 Notch1	 NOTCH1	 CST	 3268	
184	 Notch3	 Notch3	 NOTCH3	 Santa	Cruz	 sc-5593	
185	 N-Ras	 N-Ras	 NRAS	 Santa	Cruz	 sc-31	
186	 p21	 p21	 CDKN1A	 Santa	Cruz	 sc-397	
187	 p27	KIP	1	 p27-Kip-1	 CDKN1B	 Abcam	 ab32034	
188	 p27/KIP	1	(phospho	T198)	 p27_pT198	 CDKN1B	 Abcam	 ab64949		
189	 p27/Kip1	(phospho	T157)	 p27_pT157	 CDKN1B	 R&D	Systems	 AF1555	
190	 p38	MAPK	 p38	 MAPK14	 CST	 9212	
191	 p38	MAPK	(phospho	T180/Y182)	 p38_pT180_Y182	 MAPK14	 CST	 9211	
192	 p44/42	MAPK	 p44-42-MAPK	 MAPK3	 CST	 4695	
193	 p53	 p53	 TP53			 CST	 9282	
194	 p70	S6	Kinase	(phospho	T389)	 p70-S6K_pT389	 RPS6KB1	 CST	 9205	
195	 p70/S6K1	 p70-S6K1	 RPS6KB1	 Abcam	 ab32529	
196	 p90RSK	(phospho	T573)	 p90RSK_pT573	 RPS6K	 CST	 9346	
197	 PAI-1	 PAI-1	 SERPINE1	 BD	Biosciences	 612024	
198	 PAR	 PAR	 PAR	 Trevigen	 4336-BPC-100	
199	 PARK7/DJ1	 DJ1	 PARK7	 Abcam	 ab76008	
200	 PARP-1	 PARP1	 PARP1	 Santa	Cruz	 sc-7150	
201	 Paxillin	 Paxillin	 PXN	 Epitomics	 1500-1	
202	 P-Cadherin	 P-Cadherin	 CDH3	 CST	 2130	
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203	 PCNA	 PCNA	 PCNA	 Abcam	 ab29	
204	 Pdcd-1L1	 Pdcd-1L1	 CD274	 Santa	Cruz	 sc-19090	
205	 Pdcd4	 Pdcd4	 PDCD4	 Rockland	 600-401-965	
206	 PDGFR	beta	 PDGFR-b	 PDGFRB	 CST	 3169	
207	 PDK1	 PDK1	 PDPK1	 CST	 3062	
208	 PDK1	(phospho	S241)	 PDK1_pS241	 PDPK1	 CST	 3061	
209	 PD-L1	 PD-L1	 CD274	 CST	 13684	
210	 PEA-15	 PEA-15	 PEA15	 CST	 2780	
211	 PED/PEA-15	(phospho	S116)	 PEA-15_pS116	 PEA15	 Invitrogen	 44-836G	
212	 PI3	Kinase	p110	alpha	 PI3K-p110-a	 PIK3CA		 CST	 4255	
213	 PI3K	p110	beta	 PI3K-p110-b	 PIK3CB	 Santa	Cruz	 sc-376412	
214	 PI3K	p85	 PI3K-p85	 PIK3R1	 Millipore	 06-195	
215	 PKA	RI	alpha	 PKA-a	 PRKAR1A	 CST	 5675	
216	 PKC	alpha	 PKC-a	 PRKCA		 Millipore	 05-154	
217	 PKC	alpha	(phospho	S657)	 PKC-a_pS657	 PRKCA		 Millipore	 06-822	
218	 PKC	beta	II	(phospho	S660)	 PKC-b-II_pS660	 PRKCA,	PRKCB		
PRKCD,	PRKCE			
PRKCH,	PRKCQ	
CST	 9371	
219	 PKC	delta	(phospho	S664)	 PKC-delta_pS664	 PRKCD	 Millipore	 07-875	
220	 PKM2	 PKM2	 PKM2	 CST	 4053	
221	 PLC	gamma2	(phospho	Y759)	 PLC-gamma2_pY759	 PLCG2	 CST	 3874	
222	 PLK1	 PLK1	 PLK1	 CST	 4513	
223	 PMS2	 PMS2	 PMS2	 Novus	Biologicals	 22510002	
224	 PRAS40	 PRAS40	 AKT1S1	 Invitrogen	 AHO1031	
225	 PRAS40	(phospho	T246)	 PRAS40_pT246	 AKT1S1	 Life	Technologies	 441100G	
226	 PREX1	 PREX1	 PREX1	 Abcam	 ab102739	
227	 Progesterone	Repector	 PR	 PGR	 Abcam	 ab32085	
228	 PTEN	 PTEN	 PTEN	 CST	 9552	
229	 Puma	 Puma	 BBC3	 CST	 4976	
230	 PYGM	 PYGM	 PYGM	 Novus	Biologicals	 H00005837-M10	
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231	 Rab11	 Rab11	 RAB11A,B	 CST	 3539	
232	 Rab25	 Rab25	 RAB25	 CST	 4314	
233	 Rad50	 Rad50	 RAD50	 Millipore	 05-525	
234	 Rad51	 Rad51	 RAD51	 CST	 8875	
235	 Raptor	 Raptor	 RPTOR	 CST	 2280	
236	 Rb	 Rb	 RB1	 CST	 9309	
237	 Rb	(phospho	S807/S811)	 Rb_pS807_S811	 RB1	 CST	 9308	
238	 RBM15	 RBM15	 RBM15	 Novus	Biologicals	 21390002	
239	 Rheb	 Rheb	 RHEB	 R&D	Systems	 MAB3426	
240	 Rictor	 Rictor	 RICTOR	 CST	 2114	
241	 Rictor	(phospho	T1135)	 Rictor_pT1135	 RICTOR	 CST	 3806	
242	 Rock-1	 Rock-1	 ROCK1	 Santa	Cruz	 sc-5560	
243	 RPA32	 RPA32	 RPA32	 CST	 2208	
244	 RPA32	(Phospho	S4/S8)	 RPA32_pS4_S8	 RPA32	 Bethyl	 A300-245A	
245	 RSK	 RSK	 RPS6KA1		
RPS6KA2		
RPS6KA3	
CST	 9347	
246	 S6	(phospho	S235/S236)	 S6_pS235_S236	 RPS6	 CST	 2211	
247	 S6	(phospho	S240/S244)	 S6_pS240_S244	 RPS6	 CST	 2215	
248	 S6	Ribosomal	Protein	 S6	 RPS6	 CST	 2317	
249	 SCD	 SCD	 SCD	 Santa	Cruz	 sc-58420	
250	 SDHA	 SDHA	 SDHA	 CST	 11998	
251	 SF2/ASF	 SF2	 SRSF1	 Invitrogen	 32-4500	
252	 Shc	(phospho	Y317)	 Shc_pY317	 SHC1	 CST	 2431	
253	 SHP-2	(phospho	Y542)	 SHP-2_pY542	 PTPN11	 CST	 3751	
254	 SLC1A5	 SLC1A5	 SLC1A5	 Sigma-Aldrich	 HPA035240	
255	 Smac/Diablo	 Smac	 DIABLO	 CST	 2954	
256	 Smad1	 Smad1	 SMAD1	 Abcam	 ab33902	
257	 Smad3	 Smad3	 SMAD3	 Abcam	 ab40854	
258	 Smad4	 Smad4	 SMAD4	 Santa	Cruz	 sc-7966	
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259	 Snail	 Snail	 SNAI1	 CST	 3895	
260	 SOD2	 SOD2	 SOD2	 CST	 13141	
261	 Sox2	 Sox2	 SOX2	 CST	 2748	
262	 Src	 Src	 SRC	 Millipore	 05-184	
263	 Src	(phospho	Y527)	 Src_pY527	 SRC,	YES1,	FYN		
FGR		
CST	 2105	
264	 Src	Family	(phospho	Y416)	 Src_pY416	 SRC,	LYN,	FYN		
LCK,	YES1,	HCK	
CST	 2101	
265	 Stat3	 Stat3	 STAT3	 CST	 4904	
266	 Stat3	(phospho	Y705)	 Stat3_pY705	 STAT3	 CST	 9131	
267	 Stat5a	 Stat5a	 STAT5A	 Abcam	 ab32043	
268	 Stathmin	1	 Stathmin-1	 STMN1	 Abcam	 ab52630	
269	 Syk	 Syk	 SYK	 Santa	Cruz	 sc-1240	
270	 Tau	 Tau	 TAU	 Millipore	 05-348	
271	 TAZ	 TAZ	 TAZ	 CST	 4883	
272	 TFAM	 TFAM	 TFAM	 CST	 7495	
273	 TIGAR	 TIGAR	 C12ORF5	 Abcam	 ab137573	
274	 Transferrin	Receptor	 TFRC	 TFRC	 Novus	Biologicals	 22500002	
275	 Transglutaminase	II	 Transglutaminase	 TGM2	 Lab	Vision	 MS-224-P1	
276	 TSC1/Hamartin	 TSC1	 TSC1	 CST	 4906	
277	 TSC2/Tuberin	(phospho	T1462)	 Tuberin_pT1462	 TSC2	 CST	 3617	
278	 TTF1	 TTF1	 NKX2-1	 Abcam	 ab76013	
279	 Tuberin	 Tuberin	 TSC2	 Abcam	 ab32554	
280	 Twist	 TWIST	 TWIST2	 Santa	Cruz	 sc-81417	
281	 Tyro3	 Tyro3	 TYRO3	 CST	 5585	
282	 UBAC1	 UBAC1	 UBAC1	 Sigma-Aldrich	 HPA005651	
283	 Ubiquityl	Histone	H2B	 Ubq-Histone-H2B	 H2BFM	 Millipore	 05-1312	
284	 UGT1A	 UGT1A	 UGT1A1	 Santa	Cruz	 sc-271268	
285	 VDAC1/Porin	 Porin	 VDAC1	 Abcam	 ab14734	
286	 VEGF	Receptor	2	 VEGFR-2	 KDR	 CST	 2479	
 33 
287	 **VHL-EPPK1**	 VHL-EPPK1	 EPPK1	 BD	Biosciences	 556347	
288	 Vimentin	 Vimentin	 VIM	 Dako	 M0725	
289	 Wee1	 Wee1	 WEE1	 CST	 4936	
290	 XBP1	 XBP1	 XBP1	 Santa	Cruz	 sc-32136	
291	 XIAP	 XIAP	 XIAP	 CST	 2042	
292	 XPA	 XPA	 XPA	 Santa	Cruz	 sc-56813	
293	 XPF	 XPF	 XPF	 Abcam	 ab3299	
294	 XRCC1	 XRCC1	 XRCC1	 CST	 2735	
295	 YAP	 YAP	 YAP1	 Santa	Cruz	 sc-15407	
296	 YAP	(phospho	S127)	 YAP_pS127	 YAP1	 CST	 4911	
297	 YB1	 YB1	 YBX1	 Novus	Biologicals	 17250002	
298	 YB1	(phospho	S102)	 YB1_pS102	 YBX1	 CST	 2900	
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Western Blot 
Protein was isolated from NK cells treated with a non-targeting siRNA pool or AMPKα1/2 
siRNA 24 hours post-electroporation. To analyze protein expression, cells were lysed in 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% 
sodium deoxycholate; 150 mM NaCl; 1 mM EDTA) supplemented with a complete protease 
inhibitor cocktail (Roche, Basel, Switzerland). The same amount of proteins was separated by 
12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to 
nitrocellulose membranes using the Transfer Blot Turbo (Biorad, Hercules, California). The 
primary antibodies used were monoclonal anti-AMPKα and anti–glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (both Cell Signaling, Danvers, MA. The membranes were blotted 
with appropriate primary antibodies and horseradish peroxidase (HRP)–conjugated secondary 
antibody to detect the proteins of interest. The anti-mouse and anti-rabbit horseradish peroxidase 
(HRP)–conjugated secondary antibodies were from Santa Cruz Biotechnology (Dallas, TX). 
NMR 
The global metabolic profile of licensed and unlicensed NK cells was examined using NMR. 
Ten million NK cells were lysed with 0.5 mL of polymer vortex beads in a 3 mL solution of 
methanol and water (2:1). The suspended cells were vortexed, flash-frozen in liquid nitrogen, 
and allowed to thaw in ice. After three vortex–freeze–thaw cycles, the samples were centrifuged 
for 10 minutes, and the supernatant, containing water-soluble metabolites, was extracted. The 
supernatant was placed in a lyophilizer overnight where the samples were freeze-dried to purify 
the metabolites. The metabolites were then dissolved in 600 µL of deuterium oxide (2H2O), 36 
µL of PBS, and 4 µL of 80 mM DSS standard (4,4-dimethyl-4-silapentane-1-sulfonic acid). 
Deuterium oxide was used for field-locking, PBS was used to control the pH of the solution, and 
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DSS was used as an internal standard with a final concentration of 0.5 mM in 640 µL of 
solution. NMR sample preparation was completed by placing the sample solutions in NMR 
tubes.  
 
NMR spectra were obtained using a Bruker AVANCE III HD 500 MHz NMR scanner (Bruker 
BioSpin Corporation, The Woodlands, TX). The spectrometer was equipped with a cryogenic 
temperature probe to improve the sensitivity of the acquisition. A pre-saturation technique was 
implemented for water suppression. The spectra were obtained using a 90° flip angle, 10,240 Hz 
bandwidth, 1.09 s acquisition time (16,000 complex points), and 6.0 s scan delay to allow for 
complete T1 relaxation of the metabolites. A total of 256 scans were collected and averaged for 
each spectrum. The time domain signal was apodized using an exponential function.  
 
The acquired NMR spectra were phase-corrected to produce Lorentzian peaks, baseline-
corrected to reduce noise and flatten the spectra, and reference-corrected to set the DSS 
reference peak to 0.00 ppm. Peak identification was performed using Chenomx NMR Suite 8.1 
software (Chenomx Inc., Edmonton, Canada). The identified peaks were then integrated using 
MestReNova software (Mestrelab Research, A Coruña, Spain), and the intensities were 
converted to metabolite concentrations. 
Statistics 
Prism was used to calculate p values. The statistical tests used are indicated in the figure 
legends. For pairwise analysis of licensed and unlicensed cells from the same donor, we used 
paired t tests. Otherwise, unpaired t tests were used. 
Metabolite concentrations were averaged separately for the licensed and unlicensed groups and 
compared using an unpaired, two-sample, two-tailed t-test with equal variance and correction 
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for multiple comparisons using the Holm-Sidak method. RPPA differences were identified by 
calculating multiple unpaired t-tests.*p£0.05, **p£0.01, ***p£0.001.
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Chapter 3: Specific Aims 
 
Specific Aim One: Understanding intrinsic mechanistic differences between licensed and 
unlicensed NK cells 
Unlicensed NK cells are hypo responsive against targets such as cancer cells (Kim et al., 
2005). I hypothesized that licensed NK cells are functional due to the extrinsic interaction of 
inhibitory KIR with self-HLA leading to an intrinsic signal that occurs during education 
rendering licensed NK cells functional, able to proliferate, and survive. To establish preliminary 
data on mechanisms and models of NK cell licensing, I determined the ability of the two subsets 
cells to expand ex vivo, measured their telomere lengths using mass cytometry coupled with 
telofish, and identified signaling pathway differences by reverse phase protein array. 
 
Specific Aim Two: Understanding the role of metabolism in licensed and unlicensed NK 
cell cytotoxicity  
Observations from aim one suggested that expanded licensed NK cells might be more 
metabolically active than unlicensed NK cells. p38 and AMPK signaling after KIR cross-linking 
was increased in the licensed NK cell subsets. First I determined the engagement of glycolysis 
and mitochondrial respiration between the two subsets. Next I determined the necessity of 
mitochondrial respiration and glycolysis pathways for NK cell cytolysis. I then assessed the role 
of AMPK signaling in NK cell expansion and NK cell cytolysis. Finally, I determined the role 
of AMPK and p38 signaling in regulating glycolysis in expanded licensed NK cells.  
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Chapter 4: Understanding intrinsic mechanistic differences 
between licensed and unlicensed NK cells 
Rationale 
 
Licensed and unlicensed NK cell subsets respond differently to targets, I hypothesized 
that the two NK cell subsets might also proliferate in vitro differently as well as engage different 
signaling pathways that contribute to the heightened sensitivity of licensed NK cells to leukemia 
targets (Kim et al., 2005). I determined the telomere lengths of licensed and unlicensed NK cells 
to try and differentiate whether unlicensed NK cells are hypo responsive because they are 
exhausted due to proliferating without inhibition (“disarming” model) or whether unlicensed 
NK cells are hypo responsive and don’t proliferate as quickly because they have never received 
their educational signal through self-HLA interaction (“arming” model). Understanding the 
pathways and mechanisms that exist between licensed and unlicensed NK cells could provide a 
method for exploiting these pathways to license all NK cells, thereby producing more 
functionally mature NK cells to fight cancer and infections. Additionally, there may be 
opportunities to turn off NK cell activation is the setting of autoimmune diseases. 
 
Because of the limited number of licensed and unlicensed NK cells that can be isolated 
from peripheral blood, we employed a novel expansion platform developed in our lab to 
elucidate the pathway differences responsible for the enhanced cytolytic functions of licensed 
NK cells.  
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4.1 Licensed and unlicensed NK cell subset distribution before and after expansion 
 
There are several findings to explain whether KIR acquisition is random or whether KIR 
expression is skewed by HLA expressed in the individual, however studies have been 
conflicting (Beziat et al., 2010; Sleiman et al., 2014). If KIR acquisition were random, we 
would expect to find equal populations of licensed and unlicensed single KIR positive NK cells 
in the peripheral blood of normal healthy donors. However, one can speculate that there may be 
other selective forces that determine which NK cell populations persist in vivo. Using flow 
cytometry, I determined the distribution or percentages of single-KIR-positive licensed or 
unlicensed NK cells fresh from the peripheral blood and after expansion ex vivo (Figure 1A). 
Fresh unexpanded licensed NK cells were more abundant in the peripheral blood than 
unlicensed NK cells. The percentage of licensed NK cells in the peripheral blood had a mean of 
18.45% compared to 10.27% of unlicensed NK cells (Figure 1B). Next, purified NK cells were 
expanded for 14 days in the presence of irradiated 721.221 leukemia feeder cells (Figure1A). 
Upon expansion for 14 days, the single-KIR-positive licensed NK cells remained at the same 
percentages, whereas unlicensed NK cell percentages decreased to a mean of 5.3% (Figure 1B). 
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Figure One: Distribution of licensed and unlicensed NK cell subsets before and after 
expansion.  
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Figure One: Distribution of licensed and unlicensed NK cell subsets before and after 
expansion. Freshly purified NK cells from the peripheral blood of normal donors were 
expanded for 14 days in the presence of 721.221 feeder cells. Percentages of licensed and 
unlicensed NK cells were determined by gating single KIR (licensed or unlicensed) positive NK 
cells by flow cytometry. Mean percent positive of licensed NK cells at day 0, 18.45 and 10.27, 
day 7, 18.6 and 16.9, and day 14, 20.03 and 5.36 for licensed and unlicensed NK cells 
respectively. Day 0 unlicensed compared to day 7(p=.032) or day 14(p=.017), respectively. 
Licensed single KIR positive cells compared to unlicensed KIR positive cells day 0 (p =.049), 
day 7(p=.0014) and day 14(p=.00069), respectively. Paired t-tests were used to obtain p-values. 
*p£0.05, **p£0.01, ***p£0.001.  
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4.2 Determining the proliferative capacity between licensed and unlicensed NK cells 
 
Licensed and unlicensed NK cell populations have unequal percentage distributions in 
the peripheral blood and after expansion with 721.221 feeder cells (Figure 1B). This finding 
suggested that the licensed NK cells are able to proliferate more or faster than unlicensed NK 
cells both ex vivo and in vivo, but could also be explained by heightened cell death in unlicensed 
NK cells. To assess the ability of the licensed and unlicensed NK cells to expand ex vivo, single-
KIR-positive licensed and unlicensed NK cells, along with KIR-negative NK cells were sorted 
by FACS (Figure 2). NK cells were first purified from buffy coat or whole blood PBMCs. NK 
cells were then gated and sorted according to the flow chart in Figure 2. KIR-negative NK cells 
were also included because this population is an immature NK cell population, KIR acquisition 
occurs later in development in NK cells (Beziat et al., 2010; Bjorkstrom et al., 2010). Sorted 
NK cell populations were expanded for 21 days in the presence of the feeder cells K562 
Clone9.mbIL21. We determined that licensed NK cells were able to expand to a mean fold 
expansion of 47,920 whereas unlicensed NK cells were only able to expand to a mean fold 
expansion of 896.5 after 3 weeks ex vivo p value=.0329 (Figure 3B). Immature KIR-negative 
NK cells expanded to a mean fold of 21,200 after 3 weeks of expansion ex vivo (Figure 3B).
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Figure Two: Gating strategy for FACS of single KIR+ and KIR- NK cells.  
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Figure Two: Gating strategy for FACS of single KIR+ and KIR- NK cells. One 
representative donor of cell sorting at day zero before expansion of fresh NK cells for signaling 
analysis experiments. NK cells were purified from whole blood or buffy coat PBMCs. NK cells 
were analyzed by flow cytometry for FACS. PBMCs cells were first gated for lymphocytes. 
Next cells were gated for CD56+ CD3- NK cells. Next cells were gated for 
KIR2DL1+KIR2DL2/3-, these cells were then gated for KIR2DL1 single positive (SP) NK cells. 
The KIR2DL1-KIR2DL2/3-  NK cells were further sorted into KIR- and KIR3DL1 SP 
populations. The KIR2DL1-KIR2DL2/3+ NK cells were further sorted into KIR2DL2/3 SP NK 
cells.  
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Figure Three: Licensed NK cells expand to greater numbers than unlicensed NK cells ex 
vivo. 
 
 
 
 46 
Figure Three: Licensed NK cells expand to greater numbers than unlicensed NK cells ex 
vivo. A) Schematic of licensed and unlicensed NK cell sorting and expansion. B) Licensed and 
unlicensed NK cells were sorted for single KIR positive NK cells either licensed or unlicensed 
as described in Figure 2. Sorted NK cell populations were expanded for 3 weeks using the 
feeder cells K562 Clone9.mbIL21. P-value=.0329. Multiple t tests correcting for multiple 
comparisons were used to obtain p-values. Error bars depict mean +/- SD. 
 47 
Figure Four: Licensed NK cells remain better killers than unlicensed NK cells after 
expansion for 3 weeks. 
 
 
 
 
 
 
 
 
 
 
 
Figure Four: Licensed NK cells remain better killers than unlicensed NK cells after 
expansion for 3 weeks. Cytotoxicity of K562 Clone9.mbIL21 expanded licensed single-KIR-
positive NK cells (black box) and expanded unlicensed single-KIR-positive NK cells (grey box) 
against 721.221 target cells. Effector target ratio is 1.25:1 Data is representative of 3 donors, 5 
licensed data points and 4 unlicensed data points. (P value=.0052). Unpaired t tests were used to 
obtain p values. Error bars are min to max. 
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4.3 Determining the telomere length between licensed and unlicensed NK cells 
 
 To attempt to understand the possible mechanism of licensing, telomere lengths were 
measured in fresh PBMCs from typed healthy normal donors using a novel method that 
combines telo-fish and cytometry by time-of-flight (CyTOF). The two models of NK cell 
licensing that we evaluated NK cells for were the arming model and the disarming model. The 
NK cell expansion data of the licensed and unlicensed NK cell subsets showed that licensed NK 
cells proliferated to greater numbers ex vivo than unlicensed NK cells. This evidence suggested 
that licensed NK cells might also proliferate more in vivo. We hypothesized that the licensed 
NK cells, which are more abundant in the peripheral blood and also expand better ex vivo would 
have shorter telomere lengths than the unlicensed NK cells. Telomeres protect the chromosomes 
from deterioration. After each cycle of replication and division, the telomeres become shorter. 
PBMCs isolated from peripheral blood were first labeled with antibodies using standard mass-
cytometry methods. After cell staining, PBMCs undergo DNA denaturation followed by 
hybridization of the peptide nucleic acid (PNA) probe conjugated to a Cy-5 fluorophore that is 
specific for the TelC region of the DNA. Lastly, a Cy-5 specific heavy metal conjugated 
antibody is used to label the telomeres with a CyTOF antibody. A representative donor using 
spanning-tree progression analysis of density-normalized events (SPADE) analysis was 
conducted to visualize telomere length from PBMC subsets and is depicted in Figure 5. SPADE 
utilizes unsupervised clustering and allows a visualization of a branch tree structure of multiple 
cell types by selecting markers for clustering (Qiu et al., 2011). 
  
 The telo-fish mass cytometry assay easily depicts telomere lengths within different 
PBMC subsets. In the SPADE tree, red is associated with higher expression and is equated to 
 49 
longer telomere lengths; blue is representative of lower expression and is equated with shorter 
telomere lengths. The size of the circle is related to the number of cell. For example, the larger 
the circle, the more cells are represented. To validate the assay, telomere lengths within PBMCs 
subsets from normal healthy donors were determined. Reasonably, naïve CD4 and CD8 T cell 
subsets have longer telomeres than their memory counterparts (Figure 5, 6) CD56dim (mature) 
NK cells have shorter telomere lengths in comparison to CD56bright (immature) NK cells (Figure 
5,6).  
 
 Licensed NK cells had a trend of shorter telomere lengths in comparison to unlicensed 
NK cell populations isolated from PBMCs from normal healthy donors (Figure 7). What we 
believe to be more interesting is the fact that unlicensed NK cells did not have shorter telomere 
lengths. We speculated that if licensed NK cells are more abundant in the peripheral blood 
because they proliferate more in vivo then the licensed NK cells would have shorter telomeres. 
This data is in favor of the “arming” model of NK cell education. However, more replicates will 
need to be performed to determine whether statistical significance can be achieved.  
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Figure Five: Spade analysis of Telomere Length Comparison between PBMC subsets. 
Figure Five:  Spade Analysis of Telomere Length Comparison between PBMC subsets. 
Representative donor of TelC MMI spade tree of PBMC gated subsets. Central Memory (CM), 
Effector Memory (EM).  
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Figure Six:  Quantitative Analysis of Telomere Length Comparison between PBMC 
subsets. 
 
 
 
 
 
 
 
 
 
 
 
Figure Six:  Quantitative Analysis of Telomere Length Comparison between PBMC 
subsets. Quantified TelC mean metal intensity (MMI) compared between PBMC subsets. TelC 
MMI was normalized to B cell to account for donor-to-donor variability. Data is representative 
of 5 donors. Central Memory (CM), Effector Memory (EM). Error bars depict mean +/- SD. 
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Figure Seven: Licensed NK cells have shorter telomere lengths than unlicensed NK cells. 
 
 
 
 
 
 
 
 
Figure Seven: Licensed NK cells have shorter telomere lengths than unlicensed NK cells. 
Telomere length of licensed and unlicensed single-KIR-positive fresh NK cells from peripheral 
blood were determined. Data is representative of 3 donors, 5 licensed data points and 4 
unlicensed data points.  Data is not significant. Error bars depict mean +/- SD. 
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4.4 Determining differences in signaling pathways between licensed and unlicensed 
NK cells 
The differences in expansion could be attributed to pro-survival pathways being turned 
on in the licensed and KIR-negative NK cell populations. Or the differences in expansion could 
be attributed to pro-apoptosis, pro-death pathways that are engaged in the unlicensed NK cell 
population. To determine what signaling differences could be playing a role in the variation of 
licensed and unlicensed NK cell populations during expansion and also variations between the 
two cell subsets and their ability to elicit a cytotoxic response against a tumor target, we 
performed signaling analysis between the three expanded cell subsets, licensed, unlicensed and 
KIR-negative NK cells.  
 
Licensed NK cells have heightened cytolytic responses against tumor targets missing 
HLA, compared to unlicensed NK cells. I have shown that licensed NK cells exhibit increased 
proliferation upon ex vivo expansion with K562 Clone9.mbIL21 feeder cells compared to 
unlicensed NK cells. Both of these characteristics of licensed NK cells suggest that licensed and 
unlicensed NK cells engage different signaling pathways that are responsible for differences in 
ex vivo expansion and NK cell mediated lysis of targets. I hypothesized that licensed NK cells 
differentially engage signaling pathways compared to unlicensed NK cells at baseline, upon 
inhibitory stimulation or upon activation. Understanding differences in baseline expression 
between licensed and unlicensed NK cells, and pathways engaged during inhibitory receptor 
signaling of licensed NK cells, may provide insight into what pathways to turn on in unlicensed 
NK cells, thus releasing the break on NK cell hypo responsiveness. Due to the low number of 
licensed and unlicensed NK cells that can be isolated from the peripheral blood, licensed, 
unlicensed and KIR-negative NK cell populations were sorted at day 0 and expanded for 21 
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days as described in 4.2. After expansion, NK cell populations were assessed by flow cytometry 
for the purity of the populations (Figure 8). All single-KIR-positive or KIR-negative NK cell 
populations had a purity of greater than 90% to ensure any signaling differences observed 
between the different subsets could be observed. 
  
Expanded licensed, unlicensed and KIR- NK cell populations were then further divided 
up into three subgroups each. Signaling at baseline, after activation, or after inhibition were the 
three subgroups. Signaling through receptor cross-linking was achieved by using antibodies 
specific for the receptor to first coat the cell receptors, followed by the addition of a secondary 
antibody to achieve receptor cross-linking to induce signaling. To assess baseline signaling, the 
baseline subgroups were cross-linked with isotype control antibodies. To assess inhibitory 
pathways that are engaged between the licensed and unlicensed populations, KIR specific anti-
KIR antibodies were used to induce cross-linking. To assess activation signaling pathways that 
are engaged between the different populations, the subgroups were cross-linked with anti-
NKp46 antibodies to induce signaling. Protein was then isolated and sent to the reverse phase 
protein array (RPPA) core at MD Anderson Cancer Center.  
 
Baseline Expression Differences Between Expanded Licensed and Unlicensed NK cells 
Many proteins were found to be differentially expressed between the expanded licensed 
and unlicensed NK cells at baseline. At baseline, expression of proteins involved in cell death or 
senescence, such as phospho-Bad, Bax, Pdcd4, CDK2 (p16INK4a) and PUMA (Gu et al., 1992; 
Jeffers et al., 2003; Howells et al., 2011; Westphal et al., 2011; Zhen et al., 2016), were 
significantly increased in the expanded unlicensed NK cells compared to the licensed NK cells 
(Figure 10). Phospho-PI3K(p85) and annexin VII expression was also increased in the 
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unlicensed NK cells at baseline. By contrast, expression of proteins involved in cell metabolism, 
such as MIF, MTCO2, SDHB, and PKM2 (King et al., 2006; Gao et al., 2007; Sakuragi et al., 
2007; Gupta and Bamezai, 2010; Yoshikawa et al., 2011), were greater at baseline in the 
licensed expanded NK cells than in the unlicensed subset (Figure 10). Interestingly, proteins 
involved in cell cycle arrest and DNA damage such as CDK1, Chk1, phopho-Chk2(pT68) and 
FoxM1 (Matsuoka et al., 1998; Geng et al., 2007; Millour et al., 2011; Wang et al., 2013), all 
had increased expression in the licensed NK cells at baseline (Figure 10). Other proteins with 
increased expression in the licensed NK cells at baseline were PRAS40, D-a-Tublin, MSH6, and 
phospho-NDRG1(pT346) (Figure 10). We also determined proteins that were upregulated in 
KIR-negative NK cells to have an immature NK cell population to compare the licensed and 
unlicensed NK cells to. The KIR-negative NK cells likely have NKG2A expression to 
contribute to their responsiveness. The KIR-negative NK cells protein expression analysis 
revealed that KIR-negative NK cells had overlapping protein expression changes with both 
licensed and unlicensed NK cells. However, the majority of protein expression in KIR-negative 
NK cells modeled protein expression similar to licensed NK cells (Figure 10). 
 
Protein Expression Differences Between Expanded Licensed and Unlicensed NK Cells 
Upon NKp46 Cross-Linking 
Following Nkp46 cross-linking to induce an activating signal, the adhesion proteins 
CD31 and CD171 were upregulated in both licensed and unlicensed expanded NK cells. 
Interestingly, after NKp46 cross-linking, phospho-ATM expression was lower in licensed than 
unlicensed expanded NK cells (Figure 11). Other proteins that were upregulated in both licensed 
and unlicensed NK cells after activation through NKp46 were EMA (MUC1), XPF, and HER2.  
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Protein Expression Differences Between Expanded Licensed and Unlicensed NK Cells 
Upon KIR Cross-Linking 
Two proteins known to affect cellular metabolism, phospho-AMPKα and phospho-p38, 
was upregulated upon KIR cross-linking in expanded licensed NK cells (Figure 12). Other 
protein expression that was found to be only significantly increased in licensed NK cells was c-
MET, JAB1, TWIST, Porin, BAP1 and phospho-NF-kB (p65_pS536). Interesting, phospho-NF-
kB expression was decreased in the unlicensed NK cells after KIR cross-linking (Figure 12). 
 
Protein Expression Changes That Occur in Both Expanded Licensed and Unlicensed NK 
Cells Upon KIR Cross-Linking 
Upon KIR cross-linking, numerous proteins were upregulated or downregulated in both 
licensed and unlicensed expanded NK cells (Figure 13A, B). Proteins involved in cell adhesion 
that had increased expression after KIR cross-linking in both licensed and unlicensed expanded 
cell subsets included proteins such as, CD44, CD49b and CD171. Other protein expression that 
was increased after KIR cross-linking in both licensed and unlicensed NK cells was N-Ras, 
Transglutaminase, Smad4, Snail, MSH2, MTOC2, HSP27, UGT1A, PRAS40, E2F1, 14-3-3-
epsilon, Src and SCD. Proteins that had decreased expression after KIR cross-linking in both 
licensed and unlicensed NK cells were YWHAZ, phospho-AKTS1, VTCN1 (B7H4) and 
TFAM.  
 
Validation of proteins involved in cellular metabolism  
 Several proteins involved in cellular metabolism were increased in licensed NK cells 
either at baseline, PKM2, or after KIR cross-linking, phospho-AMPKα and phospho-p38. 
Pyruvate kinase isoform 2 (PKM2) catalyzes the last step of glycolysis. AMP activated protein 
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kinase (AMPK) signaling and p38 mitogen activated protein kinase (p38 MAPK) signaling has 
been implicated in promoting glycolysis. Before we investigated the role of these proteins in 
licensed and unlicensed NK cell cytolysis or expansion, we verified the expression differences 
between the licensed and unlicensed NK cells. PKM2 expression was validated by flow 
cytometry. Both mean fluorescence intensity (MFI) and percent positive cells were increased in 
the licensed NK cells compared to the unlicensed NK cells (Figure 14A, B). Additionally, 
phospho-AMPKα and phospho-p38 expression levels upon KIR cross-linking were validated by 
phospho-CyTOF. Both phospho-AMPKα and phospho-p38 mean metal intensity (MMI) were 
increased in the licensed NK cells compared to the unlicensed NK cells.  
 
I hypothesize that cellular metabolism is responsible for some or all of the cytolytic 
differences observed between licensed and unlicensed NK cell subsets. 
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Figure Eight: NK cell single-KIR-positive populations after sorting on day 0 and 
expanding for 21 days. 
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Figure Eight: NK cell single-KIR-positive populations after sorting on day 0 and 
expanding for 21 days. NK cells were sorted by FACS for single-KIR-positive populations at 
day 0 and expanded for 21 days using the feeder cells K562 Clone9.mbIL21. Data is from one 
representative donor. After expansion, purity of each single KIR positive population was greater 
than 90%.
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Figure Nine: Schematic of experimental workflow to understand signaling pathways 
utilized by licensed and unlicensed NK cell subsets at baseline (isotype), inhibitory (KIR) 
and activating (NKp46) induced signaling. 
 
Figure Nine: Schematic of experimental workflow to understand signaling pathways 
utilized by licensed and unlicensed NK cell subsets at baseline (isotype), inhibitory (KIR) 
and activating (NKp46) induced signaling. First, freshly isolated NK cells from the peripheral 
blood were sorted by FACS for KIR-negative, and single-KIR-positive licensed or unlicensed 
NK cells. The sorted populations were expanded for 21 days in the presence of the feeder cells 
K562 Clone9.mbIL21 to obtain enough cells to perform signaling analysis. To induce signaling, 
the NK cell subsets were cross-linked with isotype control (baseline), KIR (inhibitory) or 
NKp46 (activating) antibodies. Protein was then isolated for reverse phase protein array 
analysis.  
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Figure Ten: Baseline (isotype) signaling in expanded licensed and unlicensed NK cells. 
 
 
 
Figure Ten: Baseline (isotype) signaling in expanded licensed and unlicensed NK cells.  
Protein expression of expanded licensed or unlicensed single-KIR-positive NK cells, and expanded KIR-negative NK cells at baseline 
(isotype cross-linking). P-values comparing licensed and unlicensed NK cells are as follows p= Annexin-VII=0.012, Bad_pS112=0.019, 
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Bax=0.010, Bcl2=0.004, p16INK4a=0.006, Pdcd4=0.0007, PDK1=0.013, PI3K-p85=0.023, Puma=0.023, CDK1=0.030, Chk1=0.038, 
Chk2_pT68=0.049, SDHB=0.007, FoxM1=0.024, MIF=0.0026, MTCO2=0.03, MSH6=0.00005, NDRG1_pT346=0.0012, PKM2=0.007, 
PRAS40=0.027. Unpaired t-tests were used to determine the p-values. Error bars are min to max. 
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Figure Eleven: Protein expression in expanded licensed and unlicensed NK cells after 
NKp46 cross-linking. 
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Figure Eleven: Protein expression in expanded licensed and unlicensed NK cells after 
NKp46 cross-linking. P-values= CD31=0.003, ATM pS1987=0.0027, EMA=0.0053, 
CD44=0.024, XPF=0.010, HER2=0.013, CD171=0.018. Unpaired t-tests were used to 
determine the p-values. Error bars are min to max. 
 
 
 
 
 
 
Figure Twelve: Upregulated protein expression in licensed NK cells upon KIR cross-
linking. 
 
Figure Twelve: Upregulated protein expression in licensed NK cells upon KIR cross-
linking. P-values= p38_pT180_Y182 .0092, c-MET .0014, JAB1 .017, TWIST .023, Porin 
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.025, BAP1 .032, NFKB1 .04, AMPKα .041. Unpaired t-tests were used to determine the p-
values. Error bars are min to max. 
 66 
Figure Thirteen: Upregulated (A) or down regulated (B) protein expression in NK cells upon KIR cross-linking regardless of 
licensing. 
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Figure Thirteen: Upregulated (A) or down regulated (B) protein expression in NK cells 
upon KIR cross-linking regardless of licensing. Unpaired t-tests were used to determine the 
p-values. All p-values were <0.05. Error bars are min to max. 
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Figure Fourteen: Validation of RRPA by flow cytometry and CyTOF. 
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Figure Fourteen: Validation of RRPA by flow cytometry and CyTOF. Flow cytometry 
analysis of PKM2 expression. A) Percent positive of PKM2 expression (p=.016) and B) Mean 
fluorescence intensity (MFI) of PKM2 (p=.0083) expression in expanded licensed single-KIR-
positive or expanded unlicensed single-KIR-positive NK cells. Unpaired t tests were used to 
determine p values. Mass cytometry analysis of phospho-AMPKα and phospho-p38 after KIR-
cross-linking in expanded licensed or unlicensed NK cells. C) Mean Metal Intensity (MMI) of 
phospho-AMPKα (p=.05), D) phospho-p38 (p=.05) Unpaired t test was used to determine p 
values. Error bars depict mean +/- SD.
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Chapter 4 Discussion 
In mice, skewing of the NK cell receptor repertoire is dependent on MHC-I level 
expression (Brodin et al., 2012). After expanding NK cells ex vivo, we observed that licensed 
NK cells are more abundant before and after expansion suggesting either that the mechanism 
that determines increased proliferative potential is stable throughout the expansion process or 
that both trans and cis licensing contribute to human NK cell repertoire skewing. The 
percentages of licensed NK cells freshly isolated from the peripheral blood is greater than 
unlicensed NK cells, suggesting that the HLA environment in the individual skews the KIR 
repertoire and selects for NK cell populations expressing licensed KIR. If KIR expression was 
stochastic and proliferation was equal, we would expect KIR distribution frequency to be the 
same between licensed and unlicensed NK cells. Additionally, sorted licensed NK cells 
expanded to greater numbers ex vivo compared to unlicensed NK cells and increased expression 
of many pro-apoptotic proteins were observed in the unlicensed NK cell subsets after expansion. 
Studies by Brodin et al., observing enhanced survival in educated NK cell subsets in mice also 
agree with our findings. This suggests that the licensed NK cells might also proliferate in vivo 
more than unlicensed NK cells, perhaps in the setting of viral infections or tumor occurrence 
when HLA is down regulated, like in the setting of 721.221 and K562 Clone9.mbIL21 ex vivo 
expansions. 
 
 
Sorted licensed NK cells expanded to notably greater numbers than unlicensed NK cells, 
even though the telomeres of the licensed NK cells were slightly shorter than unlicensed NK 
cells, but this difference was not statistically significant. Suggesting, differences in ex vivo 
expansion could not be attributed to NK cell exhaustion of unlicensed cells in vivo resulting in 
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shorter telomeres. Although licensed NK cells are inhibited or disarmed via KIR, we propose 
that NK cells require an arming signal (arming model) to function, rather than a disarming 
signal, because they proliferate more and have shorter telomeres than unlicensed cells. We 
would expect to see unlicensed NK cells with shorter telomere lengths due to over stimulation in 
vivo if the disarming model is true. KIR-negative NK cells were also able to expand 
considerably ex vivo, likely due to NKG2A expression, because NKG2A expression precedes 
KIR expression and is also thought to contribute to NK cell education (Braud et al., 1998; 
Yawata et al., 2008; Beziat et al., 2010; Bjorkstrom et al., 2010; Lisovsky et al., 2015). We did 
not verify NKG2A expression as this was not the main focus of the study, our interest in using 
KIR-negative NK cells stemmed from using an immature NK cell population to compare with 
the licensed and unlicensed NK cell expansion.  
 
We propose that the arming signal through the inhibitory KIR endows the licensed NK 
cells with proliferative potential, allowing them to expand to greater numbers than unlicensed 
NK cells. Further studies are needed to clarify whether licensed NK cells and NKG2A-positive, 
KIR-negative NK cells engage the same metabolic signaling pathways. 
 
At baseline, many proteins involved in cell death and senescence were upregulated in the 
unlicensed KIR-positive cells. This increase in cell death and senescence related proteins could 
explain the marked decrease in expansion capabilities of the unlicensed NK cells. This provides 
further evidence that an arming signal is needed for an NK cell to proliferate as well as assume 
full cytolytic effector functions. Interestingly, proteins involved in cell cycle arrest have 
increased expression at baseline in the expanded licensed NK cells, which is surprising as this 
subset is able to proliferate well. This could be explained by the decrease in phospho-ATM 
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expression in expanded licensed NK cells upon NKp46 cross-linking. ATM interacts with 
CHK1/2, CDK1, alpha-tubulin and FoxM1 (proteins that had increased expression in licensed 
NK cells at baseline) (Matsuoka et al., 1998; Geng et al., 2007; Millour et al., 2011; Wang et 
al., 2013), and a decrease in ATM signaling could prevent cell death.  
 
We also characterized KIR-negative NK cell protein expression at baseline. KIR-
negative NK cells are immature developmentally compared to KIR-positive NK cells. KIR-
negative NK cells likely have expression of NKG2A. NKG2A can also contribute to licensing 
and NK cell responsiveness (Ivarsson et al., 2013; Lisovsky et al., 2015). My project did not 
specifically look at the role of NKG2A in NK cell education, however the KIR-negative NK 
cells are a good comparison to use to compare to licensed and unlicensed NK cells because they 
do not express KIR and they are at an earlier developmental stage and are not exhausted. There 
were some overlapping similarities in protein expression from the KIR-negative NK cells with 
both licensed and unlicensed NK cells. At baseline protein expression levels that were similar 
between unlicensed NK cells and the KIR-negative NK cells were Annexin-VII, Pdcd4, PDK1, 
phospho-PI3K and Puma. However, at baseline, there was an overwhelming similarity between 
the licensed and KIR-negative NK cell populations. The proteins that had similar expression 
level patterns between the licensed and KIR-negative NK cells were phospho-Bad, Bax, 
p16INK4a, CDK1, Chk1, SDHB, D-α-tubulin, FoxM1, Mif, MTCO2, MSH6, phospho-
NDRG1, PKM2 and PRAS40. The great parallels between licensed and KIR-negative NK cells 
suggests that the inhibitory signal through KIR and NKG2A provides an important function that 
allows both KIR-negative and licensed NK cells to proliferate more ex vivo.   
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A greater number of proteins were differentially expressed in the expanded licensed and 
unlicensed NK cells after KIR cross-linking than after NKp46 cross-linking. Previously, KIR 
signaling could only be attributed to signaling through SHP1, 2. However, after evaluating 
protein expression changes after KIR cross-linking, it can be appreciated that KIR signaling 
contributes to many pathways outside of SHP-1, 2. Phospho-AMPK-α and phospho-p38 were 
upregulated in licensed NK cells after KIR cross-linking, and both of these pathways are known 
to play a role in stress and metabolic responses. We proposed that the changes in protein 
expression after KIR cross-linking might aid in the “arming” of licensed NK cells to achieve a 
heightened cytolytic response to targets that lack HLA. The increase in phospho-AMPK-α and 
phospho-p38 led us to delve deeper into the metabolic pathways engaged by the licensed and 
unlicensed NK cell subsets. 
 
Some proteins had similar expression patterns after both KIR and NKp46 cross-linking 
such as CD44 and CD171. Both of these proteins are involved in cell-to-cell interactions and 
cell adhesion. This suggests that NK receptor engagement alone can increase expression of 
proteins involved in adhesion that will aid the NK cell in forming a tight synapse with the target 
cell and achieve NK cell mediated cytolysis. Protein expression levels that increased in both 
licensed and unlicensed NK cells after NKp46 cross-linking included EMA (MUC1), XPF and 
HER2, and the role of these proteins have not been explored in NK cells. Many of the pathway 
differences that we have described were in expanded NK cells, which are in a heightened 
activation state compared to NK cells freshly isolated from peripheral blood. We believe this 
model system is applicable to fresh NK cells because, after expansion, differences in 
cytotoxicity were still observed between expanded licensed and unlicensed NK cells, as has 
been shown in freshly isolated NK cells. Our findings open up many new opportunities for 
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understanding NK cell activation and inhibition signaling pathways that could provide 
targetable treatment options to improve NK cell immunotherapy. 
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Chapter 5: Understanding the role of metabolism in licensed and 
unlicensed NK cell cytotoxicity  
Rationale 
 
Preliminary results from aim one revealed that p-AMPKα and p-p38 levels were 
increased in licensed NK cells compared to unlicensed NK cells upon KIR cross-linking (Figure 
12, 14 C, D). AMPK and p38 signaling are both involved in sensing stress and have been show 
to increase glycolysis. At baseline, PKM2 levels were increased in licensed NK cells (Figure 10, 
14 A, B). PKM2 catalyzes the last rate-limiting step to convert phosphoenolpyruvate into 
pyruvate. All of these proteins are involved in the glycolysis pathway, suggesting that glycolysis 
may be different in the two subsets. AMPK is activated when AMP levels are high indicating a 
need for increased energy production. Based on these data, we hypothesized that KIR signaling 
during development leads to increased AMPK, which enhances glycolysis and thereby enables 
increased lytic function in licensed cells. Licensing can be measured by performing cytotoxicity 
or degranulation assays against 721.221 leukemia target cells as a surrogate for cytotoxicity. 
Licensed NK cells have greater cytotoxicity and degranulation compared to unlicensed NK 
cells. Studies observing T cell metabolism have provided evidence that metabolism can be  
responsible for differences in effector function. We further investigated the role of metabolism 
in the licensed and unlicensed NK cells. We also determined the role AMPK and p38 signaling 
play in regulating glycolysis in licensed NK cells.  
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5.1 Determining the effect AMPK signaling has on NK cell cytotoxicity  
 
The increase in phospho-AMPKα levels after KIR cross-linking in licensed NK cells 
suggested that AMPK signaling may be playing a role in the heightened responsiveness licensed 
NK cells have against their targets. Using the pharmacological AMPK agonist, Metformin, and 
AMPK inhibitor Compound C, I determined whether AMPK activation or inhibition altered 
licensed or unlicensed NK cell cytotoxicity against 721.221 targets. I hypothesized that AMPK 
activation in the unlicensed NK cell subsets will enhance their cytolytic ability against 721.221 
targets. However, activation of AMPK with Metformin did not lead to a significant increase in 
721.221 cell lysis in either licensed or unlicensed NK cells (Figure 15). Inhibition of AMPK 
with Compound C prevented all cytolytic ability in both licensed and unlicensed NK cells 
(Figure 15).  
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Figure Fifteen: The effect of AMPK activation or inhibition on licensed and unlicensed NK 
cell cytotoxicity.  
 
 
Figure Fifteen: The effect of AMPK activation or inhibition on licensed and unlicensed NK 
cell cytotoxicity. Licensed and unlicensed NK cells were incubated with 2mM Metformin or 
10uM Compound C for 3 hours prior to starting the cytotoxicity assay. NK cells were washed 
and co-cultured with 721.221 targets at a 10:1 effector target ratio for 4 hours. Percent lysis of 
721.221 targets by licensed or unlicensed NK cells is shown. Error bars represent mean +/- min 
to max.   
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5.2 Determining the effect AMPK signaling has on NK cell expansion 
AMPK signaling in licensed and unlicensed NK cells was investigated for its role in NK 
cell expansion. As shown above in Figure 3, the licensed NK cells expanded to greater numbers 
than unlicensed NK cells. To determine whether the increased expansion abilities of the licensed 
NK cells was attributed to AMPK signaling, licensed and unlicensed NK cells were sorted and 
then expanded as described in Figure 3A, with the addition of Metformin or Compound C, to 
determine the effect AMPK activation or inhibition, respectively, has on NK cell expansion. 
Opposing to my hypothesis, activating AMPK signaling with Metformin resulted in decreased 
expansion of both licensed and unlicensed NK cell subsets. This suggested that AMPK plays an 
important role in NK cell proliferation, because inhibiting AMPK signaling killed NK cells, 
however prolonged activation of AMPK was also detrimental to NK cell expansion. It is 
understandable that prolonged activation of AMPK prevents NK cell expansion because AMPK 
is involved in stress responses. Stressing the NK cells for a long period of time was harmful to 
NK cell proliferation.
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Figure Sixteen: The effect of AMPK activation or inhibition on licensed and unlicensed 
NK cell expansion.  
 
 
Figure Sixteen: The effect of AMPK activation or inhibition on licensed and unlicensed 
NK cell expansion. Licensed and unlicensed NK cells were sorted by FACS at day zero. Sorted 
NK cells were expanded for 21 days with the feeder cells K562 Clone9.mbIL21 in the presence 
of 2mM Metformin or 10uM Compound C. NK cell fold expansion with no drug, Metformin, or 
Compound C. Licensed NK cells are shown with a solid line, unlicensed NK cells are shown 
with a dashed line. No drug, circle; Metformin, square; Compound C, triangle.  
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5.3 Evaluation of licensed and unlicensed NK cell subsets utilization of glycolysis 
and mitochondrial respiration 
The upregulation of PKM2, phospho-AMPKα and phospho-p38 in expanded licensed 
NK cells at baseline led us to investigate metabolic pathways in the two subsets. Using a 
Seahorse XFe96 analyzer (Agilent Technologies) that measures extracellular acidification rate 
(ECAR) and oxygen consumption rate (OCR), we determined the extent to which licensed and 
unlicensed NK cells depend on glycolysis and mitochondrial respiration. We performed the mito 
stress test and the glycolysis stress tests to observe licensed and unlicensed NK cell’s ability to 
engage mitochondrial respiration and glycolysis, respectively, under stress conditions. ECAR is 
largely determined by the rate of glycolysis and OCR is an indicator of mitochondrial 
respiration. First we assessed mitochondrial respiration and observed that there was no 
significant difference in OCR between expanded licensed and unlicensed NK cells (Figure 17). 
Next we measured ECAR to calculate glycolysis, glycolytic capacity and glycolytic reserve. 
Glycolysis in the seahorse assay is a measurement of glycolysis in a cell after a saturating 
amount of glucose is added. Glycolytic capacity refers to the maximum glycolytic rate after 
mitochondrial respiration is inhibited. Glycolytic reserve is representative of the maximum 
glycolytic function of a cell and is calculated by glycolytic capacity-glycolysis. Expanded 
licensed NK cells exhibited greater glycolysis, higher glycolytic capacity and greater glycolytic 
reserve than unlicensed expanded NK cells (Figure 18).  
 
Since our metabolism studies were conducted in expanded licensed and unlicensed NK 
cells, we wanted to determine whether differences in glycolysis could also be observed in fresh 
NK cells isolated from the peripheral blood of normal healthy donors. We assessed glycolysis in 
fresh licensed and unlicensed NK cells. First we determined glycolytic capacity and glycolytic 
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reserve in unstimulated fresh licensed and unlicensed NK cells. We observed a trend toward 
lower glycolysis in unlicensed NK cells compared to licensed NK cells, albeit not significant 
(Figure 19). We also stimulated the licensed and unlicensed NK cells during the glycolysis 
stress test assay with particles made from K562 Clone9.mbIL21 by our collaborators in Florida 
(Oyer et al., 2016). Stimulation with the particles increased the rate of glycolysis, however there 
was not a significant difference in the rate of glycolysis between the licensed and unlicensed NK 
cell subsets (Figure 20). For this experiment, only two donors were used due to donor 
availability, further experiments will need to include more donors in order to determine whether 
the observed increase in glycolysis in licensed NK cells is true in fresh human NK cells. 
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Figure Seventeen: Expanded licensed versus unlicensed NK cell assessment of mitochondrial respiration.  
 
 
 
 
 
 
 
 
 
Figure Seventeen: Expanded licensed versus unlicensed NK cell assessment of mitochondrial respiration.  
A) Mitochondrial Respiration, one representative donor. B) Basal Respiration and spare respiratory capacity calculated for 3 donors (5 
licensed populations, 4 unlicensed populations). Error bars measure standard deviation. 
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Figure Eighteen: Expanded licensed versus unlicensed NK cell assessment of glycolysis.  
 
Figure Eighteen: Expanded licensed versus unlicensed NK cell assessment of glycolysis. A) Glycolytic function, one representative 
donor. B) Glycolysis (p=.026), glycolytic capacity (p=.0019), and glycolytic reserve (p=.036) calculated for 3 donors (5 licensed 
populations, 4 unlicensed populations). Multiple t tests (unpaired) were used to determine p values. Errors bars measure min to max. 
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Figure Nineteen: Assessment of glycolysis in fresh NK cells.   
 
 
Figure Nineteen: Assessment of glycolysis in fresh NK cells.  
NK cells were purified from peripheral blood from typed KIR/HLA normal donors. NK cells 
were sorted by FACS for single KIR positive licensed or unlicensed NK cell populations A) 
Fresh NK cell glycolytic capacity. B) Fresh NK cell glycolytic reserve. Error bars measure min 
to max. 
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Figure Twenty: Assessment of glycolysis in fresh NK cells after stimulation with PM21. 
 
Figure Twenty: Assessment of glycolysis in fresh NK cells after stimulation with PM21. 
Glycolytic capacity and glycolytic reserve were determined after Stimulating the freshly isolated 
licensed and unlicensed NK cell populations with PM21. Data is representative of two donors. 
Error bars measure min to max.  
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5.4 Determining the role of glycolysis and OXPHOS in licensed and unlicensed NK 
cell cytolytic effector function 
Licensed NK cells achieved greater cytolysis of 721.221 leukemia targets (Figure 4). 
Metabolism has been shown to play a role in T cell effector functions, so we next investigated 
whether the increase in cytolysis of licensed NK cell targets could be attributed to the increase 
in glycolysis. Using metabolic pathway inhibitors, we investigated whether licensed and 
unlicensed NK cells depend on glycolysis or mitochondrial respiration for cytotoxic effector 
functions. In order to achieve inhibition of the different metabolic pathways in the NK cells 
without also inhibiting the metabolic pathways in the tumor target, which might change the 
sensitivity of the targets to NK cell mediated cytolysis, NK cells were pre-incubated in the 
presence inhibitors specific to glycolysis or OXPHOS pathways. The drug was then removed 
during the assay to prevent any off-target effects on the tumor cells.  
 
Pre-incubating expanded licensed or unlicensed NK cells in the presence of the 
glycolysis inhibitor 2-DG did not affect NK cell cytotoxicity against 721.221 targets (Figure 
21). 2-DG is a glucose analog that inhibits the enzyme hexokinase, the enzyme that catalyzes 
the first step during glycolysis. After expansion, licensed NK cells were pre-incubated in the 
presence of oligomycin, an oxidative phosphorylation inhibitor; licensed NK cells had a modest 
reduction (mean, 31%) in cytotoxicity (Figure 21). However, when unlicensed expanded NK 
cells were pre-incubated with oligomycin, a striking reduction in unlicensed NK cell 
cytotoxicity was observed (mean, 87.8%) (Figure 21). Oligomycin is an ATP synthase inhibitor 
that blocks oxidative phosphorylation by blocking ATP synthase’s proton channel. 2-DG and 
oligomycin pretreatment in combination led to mean reductions in cytotoxicity of 31.3% and 
95% in expanded licensed and unlicensed NK cells, respectively (Figure 21). Only when 2-DG 
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was combined with glucose-free medium and oligomycin to pretreat the licensed NK cells did 
we see a large reduction (mean, 88.1%) in licensed NK cell cytotoxicity to 721.221 target cells 
(Figure 21). Pre-treating licensed and unlicensed NK cells with an AMPK agonist (AICAR) did 
not affect NK cell cytotoxicity against 721.221 targets (Figure 21). These findings suggest that 
licensed NK cells utilize both mitochondrial respiration and glycolysis to elicit a cytolytic 
response against leukemia targets, however unlicensed NK cells are dependent upon 
mitochondrial respiration to perform cytolysis. Additionally, activating AMPK signaling for a 
short amount of time did not improve unlicensed NK cell cytolysis. The differences in the 
observed cytolysis between licensed and unlicensed NK cells were partially if not completely 
attributed to differences in aerobic glycolysis.  
 
 
 88 
Figure Twenty-One: Inhibition of metabolic pathways in NK cells to determine metabolic 
pathways necessary for NK cell mediated lysis. 
 
 
 
NP 
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Figure Twenty-One: Inhibition of metabolic pathways in NK cells to determine metabolic 
pathways necessary for NK cell mediated lysis. Single-KIR-positive expanded NK cells were 
pre-treated for 3 hours with the following metabolic inhibitors: Vehicle, 2mM 2DG, 40nM 
Oligomycin, 2mM+40nM Oligomycin, RPMI Glucose Free Media+ 2mM 2DG+ 40nM 
Oligomycin, 500uM AICAR. NK cells were then incubated with 721.221 target cells at a 2.5:1 
effector target ratio for 4 hours. Circles represent licensed single-KIR-positive expanded NK 
cells, squares represent unlicensed single-KIR-positive expanded NK cells. Unpaired t tests 
were used to determine p values of licensed vehicle control compared to GF+2DG+Oligo p-
value=.0008, Oligomycin treated licensed and unlicensed comparison p=0.00017, 
2DG+Oligomycin treated licensed NK cells compared to unlicensed NK cells p=0.000012. 
Error bars represent min to max.  
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5.5 Determining the role of AMPKα and p38 signaling in NK cell glucose 
metabolism  
AMPK signaling is known to play a role in promoting glycolysis, and was increased in 
licensed NK cells upon KIR cross-linking. I hypothesized that AMPK signaling would lead to 
an increase in glycolysis and that this signaling could be responsible for the increase in 
cytotoxicity of licensed expanded NK cells (Hardie, 2011; Wu and Wei, 2012). We explored the 
contribution of AMPKα and p38 signaling to the increased glycolysis in expanded licensed NK 
cells. AMPK protein expression was knocked down in expanded licensed NK cells using 
AMPKα1/2 siRNA (Figure 22). Knockdown of AMPKα1/2 did not affect expanded licensed 
NK cell cytotoxicity. Knockdown of AMPKα1/2 resulted in a decrease in glycolytic capacity 
and glycolytic reserve in expanded licensed NK cells, but this decrease was not statistically 
significant (Figure 22B). p38 protein expression was knocked down in licensed NK cells, using 
the same method as AMPK knockdown, with p38 siRNA (Figure 23). By contrast, whereas 
knockdown of p38 again did not change cytotoxicity of licensed NK cells, it did increase 
glycolytic capacity (Figure 23B). With these results, it is unclear if AMPK signaling upon KIR 
cross-linking is upstream of regulating glycolysis. However, p38 signaling downstream of KIR 
signaling negatively regulates glycolysis. This suggests that KIR signaling is important for 
tightly regulating glycolysis in licensed NK cells.  
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Figure Twenty-Two: Knockdown of AMPKα1/2 in licensed NK cells to determine the role 
AMPKα plays in NK cell glycolysis. 
 
Figure Twenty-Two: Knockdown of AMPKα1/2 in licensed NK cells to determine the role 
AMPKα plays in NK cell glycolysis. A) Knockdown of AMPK in expanded licensed NK cells 
using AMPK siRNA after 24 hours. AMPKα protein expression was determined by Western 
Blot. B) Glycolytic function of expanded licensed NK cells after AMPK knockdown. Circles 
represent control (non-targeting siRNA) and squares represent AMPKα1/2 siRNA. 
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Figure Twenty-Three: Knockdown of p38 in expanded licensed NK cells to determine the 
role p38 plays in NK cell glycolysis. 
 
 
 
Figure Twenty-Three: Knockdown of p38 in expanded licensed NK cells to determine the 
role p38 plays in NK cell glycolysis. A) Knockdown of p38 in expanded licensed NK cells 
after 24 hours. p38 expression was determined by flow cytometry. B) Glycolytic function of 
expanded licensed NK cells after p38 knockdown, circles are control no siRNA, squares are 
2uM p38siRNA, unpaired t test was used to generate a p=.037.  
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5.6 Comparison of intracellular metabolites in expanded licensed and unlicensed 
NK cells  
We hypothesized that intracellular metabolites would provide us with further insight into 
which metabolic pathways were engaged by licensed and unlicensed NK cells. Therefor we 
explored intracellular metabolites that were upregulated in licensed and unlicensed expanded 
NK cells using nuclear magnetic resonance (NMR) in collaboration with Dr. Pratip 
Bhattacharya’s lab (MD Anderson Cancer Center). 
 
Using NMR, we identified a trend toward higher (not statistically significantly) acetate 
and lactate concentrations in expanded licensed NK cells than in the unlicensed cells (Figure 
24). Conversely, higher intracellular concentrations of glutamate, aspartate, and taurine were 
found in expanded unlicensed NK cells than in the licensed subset (Figure 24). The differences 
observed in intracellular metabolite concentrations by NMR suggests that unlicensed NK cells 
may utilize different metabolic pathways that may hinder or alter their cytolysis. 
 
 
 
 94 
Figure Twenty-Four: Comparison of intracellular metabolites found in expanded licensed and unlicensed single-KIR-positive NK 
cells. 
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Figure Twenty-Four: Comparison of intracellular metabolites found in expanded licensed 
and unlicensed single-KIR-positive NK cells. Mean concentration of various metabolites 
quantified by NMR. P-values were determined by calculating standard error (SE) of licensed 
and unlicensed NK cells. 3 Donors were used in these experiments and three replicates of each 
donor were performed using NMR. P-values are as follows, glutamate p=.012, aspartate p= 
.047, taurine p= .041. NMR experiments were performed with the help of Travis Salzillo, in the 
laboratory of Dr. Pratip Bhattacharya.  
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Chapter 5 Discussion 
Mitochondrial respiration is considered an efficient, yet slow, way to produce energy. 
Aerobic glycolysis is a quick and inefficient, method of energy production but also generates 
biosynthetic substrates needed during proliferation. Mitochondrial respiration was similar 
between the expanded licensed and unlicensed NK cells; however, glycolysis, glycolytic 
capacity and glycolytic reserve were significantly greater in the expanded licensed NK cell 
population than in unlicensed cells. These findings suggest that the metabolic pathway 
responsible for the heighted cytotoxic response of licensed NK cells is not due to mitochondrial 
respiration, as both subsets utilized this pathway similarly. However, mitochondrial respiration 
was still important for both licensed and unlicensed NK cell cytolysis. This was shown by the 
decreased cytolysis of leukemia targets by licensed NK cells and the even more apparent large 
decrease of the unlicensed NK cell cytolysis after OXPHOS was inhibited with oligomycin.  
 
One explanation of the increase in glycolysis between the licensed and unlicensed NK 
cells could be the increase in PKM2 expression observed at baseline in the licensed NK cells. 
PKM2 catalyzes the last rate-limiting reaction in glycolysis to produce pyruvate. This increase 
was interesting because others have reported that resting NK cells have low levels of glycolysis 
and mitochondrial respiration, but that upon activation, glycolysis and mitochondrial respiration 
increase (Donnelly et al., 2014; Marcais et al., 2014; Keppel et al., 2015). Our results indicated 
that unlicensed NK cells, even after activation through expansion ex vivo, couldn’t increase 
glycolysis to the high levels observed by licensed NK cells. Examining glycolysis and other 
metabolic pathways in specific cell subsets is an important distinction, as bulk analysis of NK 
cell metabolism may therefore miss what is occurring within specific NK cell subsets. Until 
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now, notable intrinsic differences in licensed and unlicensed NK cells, other than their function, 
have not been described.  
 
The heightened glycolytic state of the expanded licensed NK cells compared with the 
unlicensed NK cells suggested that increased aerobic glycolysis might explain, or at least 
contribute to, the greater sensitivity of licensed NK cells to tumor targets lacking HLA. Upon 
inhibition of glycolysis with 2-DG, we did not see a reduction in cytotoxicity against parental 
cells to either the licensed or unlicensed expanded NK cells. The finding that licensed and 
unlicensed NK cells were highly cytolytic even when glycolysis was inhibited for a short period 
of time was encouraging because the tumor microenvironment will likely have less glucose 
available, as many tumors are highly glycolytic (Chang et al., 2015; Kouidhi et al., 2016). This 
has important implications for NK cell adoptive therapy for solid tumors because NK cells 
could be given in multiple doses to overcome any inhibition that prolonged exposure to low 
glucose in the tumor microenvironment. However, upon inhibition of mitochondrial respiration, 
we observed a modest reduction in the cytotoxicity of licensed NK cells and an almost complete 
inhibition of cytotoxicity in the unlicensed NK cell subset against parental cells. Inhibition of 
both mitochondrial respiration and glycolysis did not affect licensed expanded NK cell cytolytic 
function, but it did inhibit the remaining cytotoxicity of unlicensed NK cells after oxidative 
phosphorylation inhibition alone. Only after inhibiting glycolysis by pre-treating licensed NK 
cells for 3 hours in the presence of two glycolytic pathway inhibitors and an oxidative 
phosphorylation inhibitor did we observe an abolition of the expanded licensed NK cell 
cytotoxicity against 721.221 cells. Having to use two glycolytic pathway inhibitors in 
combination to abolish licensed NK cell cytotoxicity suggested that the expanded licensed NK 
cells are in a highly glycolytic state. High levels of glycolysis can be used to generate lots of 
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ATP very quickly and can be used for generating building blocks for the cell that might be 
necessary for NK cell cytolytic function. We propose that increased glycolysis was responsible 
for the increase in licensed NK cell cytotoxicity compared to unlicensed NK cells. Inhibition of 
mitochondrial respiration eliminated the ability of the unlicensed NK cells to kill their targets, 
we propose that the increase in glycolysis in the licensed NK cells is a redundant energy 
producing pathway that equips licensed NK cells to have heightened cytolysis. 
 
The signaling subunit of AMPK, AMPKα, did not appear to play a role in NK cell 
glycolysis. After activating AMPK signaling with Metformin or AICAR, licensed and 
unlicensed NK cells did not increase their cytolytic abilities against 721.221 cells. However, 
AMPK signaling does appear to be important for NK cell cytolytic ability, because inhibition of 
AMPK signaling with Compound C resulted in complete inhibition of both licensed and 
unlicensed NK cells to lyse their targets. AMPK signaling also appears to be important for NK 
cell expansion, as inhibition of AMPK signaling with Compound C resulted in complete 
inhibition of licensed and unlicensed NK cell expansion. Interestingly, constitutive activation of 
AMPK signaling with Metformin led to a decrease in both licensed and unlicensed NK cell 
expansion. This was likely due to the cells staying in a stressed state for too long, AMPK is 
involved in stress signaling and prolonged activation was detrimental to NK cell expansion. It is 
possible that AMPK could still play a role in glycolysis and licensed NK cell cytotoxicity, but 
that the effects may not be seen after knockdown for just 24 hours. This is a limitation of this 
model system as knockdown can only be achieved temporarily.  
 
The function of p38 in regulating glycolysis known to vary between cell types (Jaswal et 
al., 2007; Kalender et al., 2011; Bolanos, 2013; Liu et al., 2015). Most commonly, p38 
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functions to promote glycolysis. In contrast to its common role in other cell types, we 
demonstrated that p38 is a negative regulator of glycolysis in NK cells. Signaling through KIR 
increased p38 signaling, which to our surprise inhibited glycolysis. Future studies are needed to 
further explore how p38 is regulating glycolysis in licensed NK cells. Licensed NK cells readily 
upregulate proteins that increase glycolysis, such as PKM2 and phospho-AMPK, but also 
increase phospho-p38 expression, a negative regulator of glycolysis. This expression pattern 
suggests that glycolysis is tightly regulated in licensed NK cells, adding to the importance of the 
glycolytic pathway in these cells. Future directions will include investigating the consequence of 
too much glycolysis in licensed NK cells to better understand why glycolysis is tightly regulated 
as it pertains to NK cell effector functions and proliferation. 
 
Using NMR, increased acetate concentrations, although not significant, were observed in 
expanded licensed single KIR positive NK cells compared to the unlicensed NK cells (Figure 
24). Increased concentrations of acetate has been linked to improved CD8+ T cell memory 
responses by increasing glycolytic activity in CD8+ memory T cells (Balmer et al., 2016). The 
increased concentration of acetate further supports the highly glycolytic nature of the expanded 
licensed single KIR positive NK cells. To definitively determine the role of acetate in our 
system further studies will be necessary. Increased concentrations (not significant) of lactate 
were found in the licensed expanded NK cells (Figure 24). The increased levels of lactate were 
in agreement with the increased glycolysis that we found in the licensed NK cells compared to 
the expanded unlicensed NK cells.  
 
Higher glutamate concentrations were found in the expanded unlicensed single KIR 
positive NK cells compared to licensed NK cells. Increased glutamate concentrations have been 
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associated with inhibiting T cell PHA or CD3/CD28 induced proliferation (Lombardi et al., 
2004; Pacheco et al., 2004). Glutamate may also be playing the same inhibitory role in the 
unlicensed NK cell proliferation as the unlicensed NK cells had substantially lower proliferation 
than licensed NK cell expansion ex vivo. Higher concentrations of glutamate and aspartate in 
expanded unlicensed single-KIR-positive NK cells could suggest that unlicensed NK cells 
depend upon the glutaminolysis pathway for proliferation and cytolytic function (Figure 24).  
 
Expanded unlicensed single-KIR-positive NK cells had higher intracellular 
concentrations of the metabolite taurine compared to licensed NK cells. Taurine has been 
implicated in regulating T cell size and effector responses (Bachmann, 2012; Kaesler et al., 
2012). Additionally, taurine is an antioxidant and might be increased in the unlicensed NK cells, 
which rely heavily on mitochondrial respiration (Schaffer et al., 2014). Mitochondrial 
respiration is known to be a source of reactive oxygen species. Further studies are needed to 
examine the role of taurine in NK cells, we can speculate that taurine acts as an antioxidant in 
NK cells, however validation studies need to be performed. Further experiments will need to be 
performed to validate the NMR findings; we did not perform validations because we were 
focusing mainly on glycolysis and mitochondrial respiration between licensed and unlicensed 
NK cells. Gluconate levels were higher (not significant) in the licensed NK cells than the 
unlicensed NK cells. Gluconate metabolism is well characterized in prokaryotes, however the 
role of metabolized gluconate in humans has not been determined (Rohatgi et al., 2014).  
Gluconate is a derivative of glucose and has been demonstrated to be an antioxidant (Rohatgi et 
al., 2014). Future studies looking at the role of gluconate and NK cell function are necessary to 
determine if gluconate metabolism plays a role in NK cell education.  
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We identified novel findings between licensed and unlicensed NK cells that have not 
previously been described, however we acknowledge that there are limitations of the study. For 
instance, determining the role of AMPK and p38 signaling by performing transient knockdowns 
may not best reflect the actual role of these signaling molecules since the knockdown could only 
be achieved temporarily and the functions of these molecules might only be observed after a 
more stable knockdown. Further investigations into the effector function of licensed and 
unlicensed NK cell subsets in vivo are required, particularly in the cancer microenvironment 
where metabolite availability and pH levels will be quite different to those in the in vitro setting.  
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Summary and Future Directions 
We found that licensed and unlicensed NK cells are different in several ways that have 
not been previously appreciated. We observed that the licensed NK cells expand to greater 
numbers than the unlicensed NK cells ex vivo. Additionally, licensed NK cells have slightly 
shorter telomeres than unlicensed NK cells. This suggests an intrinsic ability in licensed NK 
cells of greater proliferation in vivo in agreement with increased proliferation during our ex vivo 
expansion. The underlying mechanisms that are responsible for heightened effector function in 
licensed NK have remained unknown until now. One reason for this is the limited number of 
licensed and unlicensed NK cells that can be obtained from the peripheral blood. By expanding 
licensed and unlicensed NK cell populations ex vivo, I determined that licensed and unlicensed 
NK cells differentially engage a variety of signaling pathways.  Of importance, unlicensed NK 
cells had increased expression of proteins involved in pro-apoptotic and pro-cell death signaling 
pathways at baseline. Conversely, expanded licensed NK cells had increased expression of 
proteins involved in cellular metabolism at baseline, suggesting that the licensed NK cells are 
more metabolically active. I investigated the cellular metabolism pathways engaged by licensed 
and unlicensed NK cells. I found that licensed NK cells had higher levels of glycolysis than 
expanded unlicensed NK cells. This is contradictory to what was previously shown, that upon 
activation NK cells upregulate glycolytic machinery and increase glycolysis (Donnelly et al., 
2014; Keppel et al., 2015).  In my findings, only the licensed NK cells could increase the rate of 
aerobic glycolysis. Mitochondrial respiration was found to be the same in both expanded 
licensed and unlicensed NK cell subsets.  
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Next, the role of mitochondrial respiration and glycolysis in NK cell mediated lysis of 
721.221 leukemia targets was determined by using inhibitors of the two pathways. Inhibition of 
mitochondrial respiration with oligomycin resulted in loss of the expanded unlicensed NK cells 
to lyse their targets, however there was only a minor suppression of expanded licensed NK cell 
mediated lysis of the 721.221 targets. Only after inhibiting the licensed NK cells with both a 
mitochondrial respiration inhibitor and two separate glycolysis inhibitors (2-DG with glucose 
free media) was a drastic decrease in NK cell mediated lysis inhibition observed. The difficulty 
inhibiting the licensed NK cells cytolysis was encouraging as using licensed NK cells in solid 
tumors might be able to withstand low nutrient conditions in the tumor microenvironment. 
  
My data raises several new questions that will need to be investigated in the field of NK 
cell education in regards to metabolism. The first question that needs to be answered is, what are 
the downstream signaling proteins after KIR signaling that leads to an increase in glycolysis in 
the licensed NK cells. It needs to be investigated whether KIR signaling keeps licensed NK cell 
inhibited allowing licensed NK cells to increase their glycolytic machinery or whether KIR 
signaling leads to an upregulation of glycolytic machinery thereby increasing glycolysis. 
Another important question that was outside the scope of my project is to determine the 
importance of aerobic glycolysis for NK cell killing. Does the aerobic glycolysis lead to a quick 
increase in energy production that allows the licensed NK cells to elicit a quick and powerful 
cytolytic response or is it that during glycolysis biosynthetic precursors, such as amino acids and 
nucleotides, are being produced allowing for the production of perforin and granzyme B. 
Another question that needs to be addressed is whether licensed or unlicensed expanded NK 
cells will be inhibited by the tumor microenvironment. Tumors are known to deplete exogenous 
levels of glucose, I assessed whether short term glycolysis inhibition had an effect on licensed 
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and unlicensed NK cell cytotoxicity, however determining how longterm decreased glycolysis 
would affect licensed and unlicensed NK cells is important when using licensed NK cells 
clinically for the treatment of solid tumors. Additionally, since tumors are highly glycolytic, the 
concentration of lactic acid in the tumor microenvironment will likely be high. Lactate 
concentrations within the tumor microenvironment can reach up to 40mM (Walenta et al., 
2000). Furthermore, one study found that treatment of NK cells with lactate impaired NK cells 
cytotoxicity (Husain et al., 2013). Another study demonstrated that tumors with lactate 
dehydrogenase (Ldha) knocked down was associated with improved cytolytic function in NK 
cells (Husain et al., 2013). Further studies are necessary to determine the effect of lactic acid on 
licensed and unlicensed NK cell effector functions.  
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Figure Twenty-Five: Summary of licensed and unlicensed NK cell characteristics. 
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Figure Twenty-Five: Summary of licensed and unlicensed NK cell characteristics. Licensed NK cells have increased 
proliferation ex vivo compared to unlicensed NK cells. Licensed NK cells have increased expression of phospho-AMPKa and phospho-
p38 upon KIR cross-linking. P38 signaling negatively regulates glycolysis signaling.  At baseline, PKM2 expression is increased in 
expanded licensed NK cells. Expanded licensed NK cells have increased glycolysis compared to unlicensed NK cells. Mitochondrial 
respiration is similar between licensed and unlicensed expanded NK cells.  
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Additionally, further evaluation of fresh licensed and unlicensed NK cell glycolysis 
engagement will need to be performed to definitively determine whether or not fresh licensed 
NK cells also exhibit heightened glycolysis. Differences will likely only be seen after activation 
of the licensed and unlicensed NK cells in vitro. Unstimulated freshly isolated NK cells, along 
with other lymphocytes have low levels of metabolism and differences between subsets have 
been difficult to observe without additional stimulation. In T cell subsets, differences in 
metabolism were only observed after activating the T cells in vitro (Guppy et al., 1993; 
Frauwirth et al., 2002; Jacobs et al., 2008; Buck et al., 2015). One major obstacle is 
overcoming limited numbers of licensed and unlicensed NK cells obtained from the donor for 
characterization. One solution could be using apheresis products; however, it will be difficult to 
justify such drastic measures for experimental purposes because individuals will still need to be 
KIR and HLA typed to determine which NK cell cells are licensed. Additionally, it is important 
to determine whether or not human unlicensed NK cells can achieve greater cytolytic properties 
by turning on glycolysis in the unlicensed NK cells. Evidence from haploidentical HSCT studies 
and mouse models studying NK cell education suggest that licensing is dynamic and can be 
altered. Future studies will need to determine whether over expression of PKM2, or inducing 
factors that regulate increased expression of PKM2 could rescue unlicensed NK cell cytolytic 
deficiency. Or perhaps, other pathways that have yet to be discovered play a greater role in NK 
cell mediated cytotoxicity.       
 
In conclusion, we have identified differences between licensed and unlicensed NK cells 
in expansion, telomere lengths, and signaling pathways, including large differences in 
glycolysis. We believe this is the first study to clearly demonstrate the mechanistic differences 
responsible for the different cytolytic functions of licensed and unlicensed human NK cells. 
 108 
These important findings will pave the way for further investigations into NK cell education and 
artificially increasing the responsiveness of unlicensed NK cells. Our results have broad and 
significant implications, both for basic NK cell biology and for the clinical use of NK cells in 
adoptive therapy. We propose these metabolic findings explain the differences in cytolytic 
function between licensed and unlicensed NK cells. Our findings are highly relevant to the 
clinic, as clinical trials of expanded NK cell infusion for the treatment of various tumor types 
are ongoing.  Our finding that licensed NK cells are highly glycolytic is important, because solid 
tumors are also highly glycolytic and the two cell types may compete for nutrients.  
Further human studies regarding selecting donors with more certain combinations of 
licensed and unlicensed NK cells and considering KIR mismatch when selecting NK cell donors 
will be important when therapeutics are used that may interfere with tumor and or immune cell 
metabolism. Additionally, our findings provide many potential paths to further explore 
differences in apoptosis, senescence, DNA damage and, potentially, alternative metabolic 
pathways that may also contribute to licensed and unlicensed NK cell function.  Using apoptosis 
inhibitors during NK cell expansion with unlicensed NK cells may provide evidence of why 
unlicensed NK cells are unable to proliferate as well. Additionally, determining what factors 
regulate the pro-apoptotic proteins in unlicensed NK cells could provide insight into why 
unlicensed NK cells cannot expand ex vivo as well as licensed NK cells.  
 
Differential intracellular metabolites such as glutamate, aspartate and taurine in 
unlicensed NK cells need to be investigated further for their role in dampening cytotoxicity in 
unlicensed NK cells. Unlicensed NK cells appeared to depend solely on mitochondrial 
respiration for their cytotoxicity; however, licensed NK cells use both mitochondrial respiration 
and glycolysis for their cytotoxicity. Other pathways such as the tricarboxylic acid cycle (TCA) 
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were not investigated in this present study. The TCA cycle could also be mediating metabolism 
differences between the two NK cell subsets that contributes to differences in their effector 
functions.  
 
 
Overall we have described novel and targetable differences between licensed and 
unlicensed NK cell metabolism that affects NK cell cytotoxicity. 
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